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AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Three leTTers ThAT chANge The people’s life
for ever
Acary Souza Bulle Oliveira1, Roberto Dias Batista Pereira2
Abstract – Amyotrophic lateral sclerosis (Als) is a neurodegenerative disease affecting the motor nervous 
system. it causes progressive and cumulative physical disabilities in patients, and leads to eventual death due 
to respiratory muscle failure. The disease is diverse in its presentation, course, and progression. We do not 
yet fully understand the cause or causes of the disease, nor the mechanisms for its progression; thus, we lack 
effective means for treating this disease. currently, we rely on a multidisciplinary approach to symptomatically 
manage and care for patients who have Als. Although amyotrophic lateral sclerosis and its variants are readily 
recognized by neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are common. 
prompt diagnosis, sensitive communication of the diagnosis, the involvement of the patient and their family, 
and a positive care plan are prerequisites for good clinical management. A multidisciplinary, palliative approach 
can prolong survival and maintain quality of life. Treatment with riluzole improves survival but has a marginal 
effect on the rate of functional deterioration, whereas non-invasive ventilation prolongs survival and improves 
or maintains quality of life. in this review, we discuss the diagnosis, management, and how to cope with 
impaired function and end of life on the basis of our experience, the opinions of experts, existing guidelines, 
and clinical trials. Multiple problems require a multidisciplinary approach including aggressive symptomatic 
management, rehabilitation to maintain motor function, nutritional support (enteric feeding, gastrostomy), 
respiratory support (non invasive home ventilation, invasive ventilation, tracheotomy), augmentative 
communication devices, palliative care, psychological support for both patients and families (because family 
members so often play a central role in management and care), communication between the care team, the 
patient and his or her family, and recognition of the clinical and social effects of cognitive impairment. social, 
bioethical, and financial issues as well as advance directives should be addressed. A plethora of evidence-based 
guidelines should be compiled into an internationally agreed guideline of best practice. The multidisciplinary 
team has changed the history of disease, with still no curative therapy available.
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Esclerose lateral amiotrófica (ELA): três letras que mudam a vida de uma pessoa. Para sempre.
Resumo – A esclerose lateral amiotrófica (elA) é doença neurodegenerativa comprometendo o sistema 
nervoso motor. ela causa comprometimento físico, progressivo e acumulativo, com óbito freqüentemente 
decorrente de falência respiratória. A enfermidade apresenta características diversas nas formas de 
apresentação, curso e progressão. Não entendemos ainda a causa ou causas dessa enfermidade, nem os 
mecanismos que regem a sua progressão; assim, tratamentos efetivos não são, até o momento, conhecidos. 
Atualmente, recomenda-se que os pacientes com elA sejam tratados com equipe multidisciplinar. embora elA 
e suas variantes sejam reconhecidas por neurologistas, cerca de 10% dos pacientes são mal diagnosticados, e 
a demora para a confirmação diagnóstica não é incomum. Diagnóstico precoce, informação do diagnóstico 
com honestidade e sensibilidade, envolvimento do paciente e sua família, e um plano de atenção terapêutica 
positivo são pré-requisitos essenciais para um melhor resultado clínico e fim terapêutico. Tratamento 
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multidisciplinar e cuidados paliativos podem prolongar a sobrevida e manter melhores aspectos de qualidade 
de vida. Tratamento com riluzol aumenta a sobrevida, mas sem alteração na deterioração funcional, enquanto 
que ventilação não-invasiva prolonga a sobrevida e aumenta ou mantém qualidade de vida. Nesta revisão, 
nós discutimos o diagnóstico, envolvimento e formas de lidar com dificuldades de funcionamento e de 
fim de vida, baseando-se na nossa experiência, nos pareceres de peritos, em guias de medicina baseada em 
evidências científicas, e nos ensaios clínicos. problemas múltiplos exigem uma abordagem multidisciplinar, 
incluindo-se tratamento sintomático agressivo, reabilitação para manter a função motora, apoio nutricional 
(alimentação entérica, gastrostomia), suporte respiratório (ventilação domiciliar não-invasiva, ventilação 
invasiva, traqueostomia), dispositivo para comunicação aumentativa, cuidados paliativos, apoio psicológico 
para ambos, pacientes e familiares (uma vez que os familiares, muitas vezes, desempenham um papel central 
na gestão e no atendimento), a comunicação entre equipe multidisciplinar, o paciente e sua família, bem 
como o reconhecimento da clínica e os efeitos sociais do declínio cognitivo. Questões sociais, financeiras e de 
bioética também devem ser consideradas. A multiplicidade de orientações com base em guias de consensos 
de melhor prática clínica devem ser fornecidas para os pacientes com elA. As orientações multidisciplinares 
têm mudado a história desta doença, ainda com nenhuma terapia curativa disponível.
pAlAVrAs-chAVe: esclerose lateral amiotrófica, diagnóstico, tratamento. 
Amyotrophic lateral sclerosis (Als) is a devastating 
neurodegenerative disorder that results in the selective 
death of motor neurons in the central nervous system. 
This progressive motor neuron degeneration leads to 
death of the patient on average three to five years after 
onset of the disease.
The unique clinical signs and symptoms and patterns 
of progression not shared by other diseases causes a pro-
found effect upon the individual with Als and her or his 
family. The stress incurred from living with illness is a 
consequence of the: disease-mitigated changes in phys-
ical and psychosocial functionin; the individual’s inter-
nal conditioning factors; no available curative therapy; fi-
nancial burden; end-of-life issues; death representing the 
main hallmark. 
charcot named Als over one hundred years ago, but it 
is only in the last 25 years that we have gained a better un-
derstanding of the disease, its treatment and the care of 
Als/MND patients. in the pursuit of early diagnosis and, 
thus, early treatment with disease specific agents such as 
riluzole, the World federation of Neurology, has reached 
an international consensus on the diagnostic definition of 
Als and they have developed criteria for the conduct of 
clinical trials in Als. 
supportive care was almost non-existent until the 
1970s. Today, clinical care is aimed both at prolonging life 
and improving quality of life. The multidisciplinary team 
has changed the history of this disease.
QUESTION OF TERMINOLOGY
Diseases that affect motor neurons can be classified 
as primary, secondary, or multisystem. The terms “motor 
neuron diseases” and “motor neuron disorders” are used 
to refer to any disease affecting motor neurons1.
The specific term “Motor Neuron Disease” (MND) is 
used in europe as progressive neurodegenerative disor-
ders with different etiologist and clinical variability, but 
a common final event: loss of upper and / or lower mo-
tor neurons. Depending on which motor neurons are af-
fected, there are four main forms identified, but they may 
overlap: (1) primary lateral sclerosis (pls) is a condition in 
which upper motor neuron signs occur in the absence of 
lower motor neuron signs, and pathologic changes are re-
stricted to the motor cortex and corticospinal tracts. it is 
characterized by spasticity, hipereflexia, Babinski’s signal. 
it represents the least common form of MND, affecting 
less those 2% of all cases; (2) progressive muscular atrophy 
(pMA) is a condition in which lower motor neuron signs 
correlating with a loss of anterior horn cells occur in the 
absence of upper motor neurons signs, and in which the 
motor neurons signs are preserved. it is characterized by 
muscle weakness and wasting, weight loss and fascicula-
tion. it represents around 5% of all MND cases; (3) progres-
sive bulbar palsy (pBp), affecting the muscles of the bulbar 
region, is characterized by dysarthria, dysphagia, tongue 
atrophy, and fasciculation. Approximately 20 % of patients 
who later develop other features of Als present initially 
with pBp; (4) Amyotrophic lateral sclerosis is the most fre-
quent MND’s presentation, having its name as MND syn-
onymous (Als / MND). it is characterized by a progressive 
degeneration of lower and upper motor neurons in the 
cerebral cortex, brainstem, and spinal cord, resulting in 
muscular atrophy, fasciculation’s, weakness and spasticity.
HISTORY AND RECOGNITION OF ALS / MND
By the 1830s, the condition of progressive muscular at-
rophy (today called spinal muscular atrophy or sMA) was 
commonly recognized, although it was not named until 
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1848 or 1850. Descriptions of sMA and pBp were added 
to the literature between 1859 and 1870. however, a land-
mark series of lectures was given by Jean-Martin charcot 
at the salpêtrière in paris, in 1874. The lectures were drawn 
from 20 clinical cases and five autopsies. it was here that 
charcot and Joffroy combined the clinical observations 
of 1) atrophic muscular weakness (amyotrophy) and spas-
ticity with 2) pathological findings, hardening of the lat-
eral columns of the spinal cord (lateral sclerosis) and le-
sions of the anterior horn. charcot named the progressive 
disorder “de la sclérose laterale amyotrophique” (amyo-
trophic lateral s clerosis or Als).
one hundred years of relative silence followed char-
cot’s naming of Als/MND. patients were diagnosed but 
not treated. They were told to go home and “put your af-
fairs in order”, nothing could be done so “there is no need 
to make a return appointment to the clinic”. The U.s. was 
revisited in 1941 by the death due to Als of the famous 
37-year-old New York baseball player, lou gehrig. hence-
forth in the U.s., Als was commonly called lou gehrig’s 
disease. interestingly, Mr gehrig received experimental in-
jections of vitamin e through a research study conducted 
by the Mayo clinic2. 
in the 1950s, new forms of the disease were recog-
nized in the form of familial and guamanian Als/MND.
1969 began an awakening of interest in Als with the 
publication of papers delivered at an international sympo-
sium devoted in Motor Neuron Disease. New techniques 
were advanced to diagnose Als, including electromyogra-
phy (eMg). New theories of the possible aetiology of Als 
were put forward, based on more complete understand-
ing of neurotransmitters in the motor system. Although 
publications remained sparse throughout the 1970s, there 
was an explosion in the late 1980s3 (Timeline).
DIAGNOSIS
The onset and early progression of Als is frequently 
insidious, and symptoms may go unrecognized and undi-
agnosed for up to 12 months. During the diagnostic eval-
uation, a patient commonly consults a variety of special-
ists, and even neurologists may not recognize Als early in 
its course. once Als is considered, many laboratory tests 
are completed before the diagnosis is made because it is 
frequently considered to be a diagnosis of exclusion.
for many years, the only published criteria for the rec-
ognition of DNM / Als was made by lambert (1957, 1969)4, 
established through electromyography. The most important 
change in diagnosis criteria occurred in 1990. The World 
federation of Neurology (WfN), in conjunction with the 
spanish fund for healthy research and the spanish Als As-
sociation, convened a task force in el escorial, spain to es-
tablish a set of clinical diagnostic criteria for Als5. The diag-
nosis of Als would be defined within the evidence of signs 
Timeline.
1830 Bell reports a case of a progressive paralysis of limbs and 
tongue with preservation of sensation.
1850 Aran names the condition of progressive muscular atrophy 
(pMA).
1853 Duchenne claims priority over Aran in reporting spinal 
Muscular Atrophy (sMA).
1865 charcot describes progressive lateral sclerosis (pls).
1870 charcot describes progressive Bulbar palsy (pBp).
1874 charcot names Als (de la sclérose laterále amyotrophique).
1883 pBp and Als united as the same syndrome.
1899 gowers considers that Als and pBp are caused by motor 
neuron degeneration.
1900 guam: Als-like description.
1930 Brain considers that Als and MND are synonymous.
1939 lou gehrig’s diagnosis and first clinical trial with vitamin e.
1941 lou gehrig dies of Als.
1943 Vitamin e injections are shown not to be effective to treat Als.
1950 levi-Montalcini describes the Nervous growth factor.
1952 hirano describes the guam Als/Dementia/parkinson 
complex.
1957 Mayo clinic – first symposium in Als/MND
1959 familial Als described with posterior column involvement.
1969 Kurland – Norris-i international symposium on Als/MND.
1969 lambert – Diagnostic criteria using electroneuromyogram 
(eMg).
1970s eMg formalized as a diagnostic tool.
1972 Amyotrophic lateral sclerosis organization of America 
(AlsoA) formed.
1973 National Amyotrophic lateral sclerosis foundation 
(NAlsf) formed.
1980 report of nerve growth factor (Ngf) published.
1984 Use of percutaneous endoscopic gastrostomy (peg) 
reported in Als.
1985 Amyotrophic lateral sclerosis Association (AlsA) formed 
as a merger of AlsoA and NAlsA.
1987 glutamate metabolism abnormality reported in Als.
1989 Motor Neuron Disease Association of the United Kingdom 
hosts the 1st international symposium of the international 
Alliance of Als/MND Associations.
1993 soD-1 gene identified.
1994 WfN el escorial criteria for diagnosis of Als published.
1995 first positive clinical trial for Als. riluzole has an effect 
on survival, prolonging life.
1996 National Neuromuscular Nurses Advisory Board is founded.
1996 American Association of Neuroscience nurses forms a 
special focus group for neuromuscular disease.
1997 American Academy of Neurology forms as special interest 
group for neuromuscular disease.
1998 WfN Airlie house criteria for diagnosis of Als revisited.
1999 American Academy of Neurology publishes an evidence-
based Als practice parameter.
2000 Transgenic mouse model of Als.
2002 13th international symposium on Als/MND – letizia Mazzini 
describes the first treatment with stem cell in Als patients.
2008 19th international symposium on Als/MND – cyanobacteria 
as a source of BMAA and possible cause of sporadic Als.
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of impairment of lower motor neuron (lMN), through clini-
cal examination, electrophysiological or neuropathologycal 
changes, associated with impairment of upper motor neu-
ron (UMN) clinically proven, with ongoing chronic and pro-
gressive (Table 2 and Table 3). it is still necessary, for diag-
nosis, the absence of electrophysiological and pathological 
findings characteristic of other diseases that explain the de-
generation of motor neurons, as well as changes in neuroim-
aging to justify the electrophysiological signals (Table 4). 
clinical diagnosis of Als has been based on finding 
evidence of progressive loss of lMN and UMN in a dif-
fuse distribution.
According to the intensity of commitment and clinical 
meetings electroneuromyographic, the diagnosis of Als / 
MND received a sub classification of diagnostic certainty: 
dfinite Als, probable Als, possible Als and suspected Als. 
Although primarily intended as an algorithm for en-
Table 1. Famous people with ALS.
Name Born profission onset Diagnostic Death
lou  gehrig 1903 Baseball 1938 06 / 1939 06 / 1941
ezzard charles 1921 Boxer 1966 1966 1975
Bob Waters 1939 football 1982 1985 1989
David Niven 1910 Actor 1980 1982 1983
charles Mingus 1922 Musician 1976 1977 1979
Jacob Javits 1904 politic 1980 1980 1986
franz rosenzweig 1886 filósopher 1921 1922 1929
Mao-Tsé-Tung 1893 politic 1976
stephen hawking 1942 cientist 1962 1962 Alive
hawking is obviously an exceptional case and one of very few people to have survived 35 years, already, with the disease.
Table 2. Signs and symptoms of UMN and LMN degeneration.
UMN signs and symptoms
  • pseudo bulbar features
    – exaggerated affect
    – forced yawning
    – exaggerated snout reflex
  • spastic tone
  • pathologic tendon reflexes
    – clonic jaw reflexes
    – pathologic spread
    – clonus
    – preserved reflex in weak, wasted limb
  • pathologic responses
    – exaggerated gag reflex
    – hoffmann response
    – extensor plantar response (Babinski’s sign)
lMN signs and symptoms
  • Atrophy
  • fasciculation’s
  • Weakness
Table 3. World Federation of Neurology Electrodiagnostic 
Proposed Criteria for LMN Degeneration. 
signs of active denervation
  • fibrillations
  • positive waves
signs of chronic partial denervation
  • Motor unit potential with increased duration
  • frequent polyphasia with instability
  • high amplitude
  • reduced recruitment except in the presence of significant 
UMN dysfunction
Table 4. World Federation of Neurology (El Escorial) criteria for 
diagnosis of ALS.
The diagnosis of Als requires
1) The presence of
•
•
•
evidence of lMN degeneration on clinical, electrophysiologic 
(including eMg features in clinically normal muscles) or 
neuropathologic examination
evidence of UMN degeneration on clinical examination
progression of the motor syndrome within a region or to 
other regions, as determined by history or examination; and
2) The absence of
•
•
electrophysiological and pathological evidence of other 
process that might explain the UMN and / or lMN signs; and
Neuroimaging evidence of other disease processes that might 
explain the observed clinical and electrophysiological signs
tering patients into clinical studies and therapeutic tri-
als, the el escorial criteria have been used clinically. There 
was, however, a consensus among researchers, since cer-
tain clinical pictures and, above all, certain electrophysio-
logical findings in some special situations were impossible 
the completion of diagnosis. The general neurologists and 
specialists in neuromuscular diseases claimed addition, 
difficulties with the necessary early Als diagnosis.
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The el escorial criteria were intended to be reviewed 
and modified. in May of 1998, in Airlie house (in Warren-
ton, Virginia, UsA), an international group of experienced 
clinic met to discuss optimal management strategies of 
Als and to revise the criteria after 4 years of clinician ex-
perience. The reviewed criteria published by the WfN-Als 
through the web6 has added a level of certainty, “probable 
Als – laboratory supported”, defined after proper appli-
cation of neuroimaging and clinical laboratory protocols, 
excluding other causes. The addition of this category was 
felt to be necessary to address the early entry of patients 
into drug trials7. The category of “suspected Als” (lMN 
in two or three regions), previously included in the el es-
corial criteria, has been dropped (Table 5).
These criteria may not be useful in diagnosing early Als. 
it may be possible that clinical trials in humans for Als have 
been mostly unsuccessful because of inclusion of only ad-
vanced patients meeting such “tight” criteria. in December 
2006, researchers around the globe met in Awaji island, Ja-
pan, to discuss about proposing the new Als criteria (Awa-
ji criteria) to facilitate detection of Als in an early stage8.
A major issue in accelerating the diagnosis of Als is 
the potential for diagnostic inaccuracy. inaccuracy is due 
to false-positive and false-negative diagnoses. even in ex-
perienced centers on Neuromuscular Disorders, misdiag-
noses are frequently reported9,10. clinical features incon-
sistent with the Als diagnosis are presented on Table 6.
for the accuracy of diagnosis are necessary tests for 
the exclusion of other diagnoses. New methods of elec-
trophysiology, neuroimaging, immunohistochemistry and 
genome analysis have been added (Table 7).
The exams results should be carefully interpreted 
(Table 8).
Magnetic resonance imaging (Mri) using a spin echo 
magnetization transfer sequence (T1 se / MT Mri) has 
been shown to be a valuable method of diagnosis. The 
findings of a bilateral symmetrical hyper intensity of the 
pyramidal tract are suggestive of Als denoting degener-
ation of corticospinal tracts11,12. 
considering the clinical and laboratory findings, the 
motor neuron diseases have been classified as Als / DNM 
(sporadic cases, family or genetically determined), Als – 
plus syndromes (multisystem neurodegenerative disease 
affecting motor neurons), the Als – related syndromes 
(represent symptomatic or secondary forms of motor 
neuron disease, with a known associated condition that 
may be causing the disease) and the Als – variants (are 
uncommon unless the patient lives in particular geograph-
ic locations) (Table 9)13,14.
EPIDEMIOLOGICAL AND OVERRAL DEMOGRAPHY
The reported incidence varies from 0.2 to 2.5 cases 
per 100,000 per year. Although estimates vary between 
countries, globally, the overall rate is approximately 2 per 
100,00015,16. This is similar to that estimated for multiple scle-
rosis (Ms) but, because Als patients die faster, the prevalence 
of Als (approximately 7/100,000) is lower than that for Ms.
A high prevalence of Als is reported in certain geo-
graphical areas, for example the pacific island of guam (50 
times that of Als in western countries), leading to specu-
lation about environmental and genetic factors as poten-
tial triggers for Als. 
Differences in incidence and prevalence estimates be-
tween countries probably reflect a combination of avail-
Table 5. Revised World Federation of Neurology criteria for diagnosis of ALS (EL Escorial revised): categories of diagnostic certainty. 
clinically Definite Als
• evidence of UMN plus lMN signs in the bulbar region and in at least two spinal regions, or
• The presence of UMN signs in two spinal regions and lMN signs in three spinal regions
clinically probable Als
• evidence of UMN plus lMN signs in at least two regions with some UMN signs rostral to lMN signs
probable, laboratory supported Als
• clinical evidence of UMN and lMN signs in only one region, or
• UMN signs alone in one region and lMN signs defined by eMg criteria in at least two muscles of different root and nerve origin in two limbs
possible Als
• UMN plus lMN in only one region, or
• UMN signs alone in two or more regions, or
• lMN signs found to rostral to UMN signs
regions: bulbar, cervical, thoracic and lumbosacral; UMN: upper motor neuron; lMN: lower motor neuron. 
Table 6. Clinical features inconsistent with the diagnosis of ALS.
Anterior visual pathway abnormalities
Autonomic nervous system dysfunction 
cognitive abnormalities associated with Alzheimer’s disease
Movement abnormalities associated with parkinson’s disease
sensory disturbance
sphincter abnormalities 
Arq Neuropsiquiatr 2009;67(3-A)
 755
Amyotrophic lateral sclerosis
oliveira and pereira
Table 7. Clinical laboratory tests frequently ordered in the 
evaluation of ALS.
general medical tests
  • Automated biochemistry panel
  • complete blood count
  • erythrocyte sedimentation rate
  • Urinalysis
Neuromuscular-related tests
  • Acetylcholine receptor antibody titters
  • collagen vascular tests
  • electrophoresis of proteins
  • endocrine evaluation: Thyroid panel; parathyroid function; 
     Testosterone level
  • enzyme evaluation: hexosaminidase A/B
  • gangliosidase antibody titters: gM1; Asialo gM1; gD1B
  • heavy metals: lead; Mercury; Aluminum; Zinc; copper
  • immunoglobulins dosage: igA; igg; igM
  • infection-related tests: syphilis; lyme; hiV; hTlV-1 and 2; 
     hepatitis B and c
  • Muscle enzymes: cK; AlT; AsT; lDh
  • Tumor markers: Alpha fetal protein; ceA; cA 15.3; cA19.9; 
    cA 125; psA; hU
  • Vitamins: Vitamin B12; folate
cerebral spinal fluid
  • electrophoresis of proteins, 
  • specific dosage of globulins
  • immune reactions
Muscle biopsy
Bone marrow biopsy
image evaluation
  • Magnetic resonance investigation
    – Brain
    – spine 
DNA evaluation
  • soD1
  • VAp B
 • Kennedy’s disease (expansion of trinucleotídeo gcc on 
    chromosome X)
Als: amyotrophic lateral sclerosis; AlT: alanine aminotransferase; AsT: 
aspartate aminotransferase; ceA: carcino embryonic antigen; cK: creatine 
kinase; lDh: lactate dehydrogenase; psA: prostate specific antigen; VDrl: 
Venereal Disease research laboratory.
Table 8. Interpretation of the laboratory investigation.
Tests that may be abnormal in typical Als
  • Muscle enzymes (cK, AlT, AsT, lDh)
  • csf protein
Tests that may be abnormal and of uncertain significance
  • lead levels
  • gangliosidase antibody titters
  • hexosaminidase A/B
  • Bone marrow
Magnetic resonance imaging
ability of medical services, diagnostic accuracy and de-
mography characteristics of the area.
The findings relating to the european subgroup study 
(italy, spain, germany) represents a similar clinical char-
acteristics of Als in other industrial countries17: a normal 
age distribution at first presentation with peak at ages 50–
59 years (26% of patients) and 60–69 years (27% of pa-
tients). About 13% of patients were younger than 40 years, 
and only 1% older than 79 years. About 39 % of the pa-
tients were women. About 82% of patients presented with 
limb onset and the remaining 18% with bulbar onset. 
Time to confirmation of diagnosis
The mean time between first symptoms and first con-
sultation with a physician was 4.9 months and with a 
neurologist was 6 months. This resulted in a mean time 
from symptom onset to confirmation of diagnosis of 17.8 
months. Many Als patients are not diagnosed until a lat-
er stage of the disease. There was little difference in the 
speed of diagnosis between Als with bulbar or limb on-
set. The diagnosis was confirmed earlier if fasciculations 
were an early and prominent sign.
The long delay from the symptom onset to diagno-
sis of Als was due to uncertainty about the significance 
of early symptoms and the wide differential diagnosis of 
early disability in Als.
FAMILIAL ALS
Most cases of Als appear sporadically but some forms 
of the disease result from mutations in the gene encod-
ing the antioxidant enzyme cu/Zn super oxide dismutase 
(soD1). several other mutated genes have also been found 
to predispose to Als including, among others, one that en-
codes the regulator of axonal retrograde transport dynactin.
A genetic risk factor accounts for 5–10% of all Als 
cases and mutation in the copper/zinc super oxide dis-
mutase 1 (soD-1) gene have been detected in approxi-
mately 20% of these cases (2–3% total patients)18,19. since 
1993, 139 mutations have been found in the soD1 gene 
on chromosome 21 with five different modes of inheri-
tance: dominant inheritance with high penetrance, dom-
inant inheritance with reduced penetrance, recessive in-
heritance, compound heterozygosity and a de novo muta-
tion. The most frequent soD1 gene mutation is the D90A 
which in many european countries is inherited as a reces-
sive trait with a characteristic slowly progressing pheno-
type though pedigrees with dominantly inherited D90A-
soD1 and an aggressive phenotype have also been report-
ed. The most frequent mutation in North America is the 
A4V which is associated with a very aggressive form of 
Als. in different populations, 12% to 23% of patients di-
agnosed with familial Als (fAls) and 2 to 7% of sporad-
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Table 9. Disorders affecting motor neurons.
primary motor neuron disorders
• idiopatic
  – Motor Neuron Disease: Als and variants
  – Monomelic Motor Neuron Disease: hirayama 
• inherited
  – Autosomal recessive
    ◆ spinal Muscular Atrophy: Type i, Type ii and Type iii
    ◆ Neuro axonal dystrophy
    ◆ hereditary bulbar palsy (hBp) (fazio-londe disease)
    ◆ hBp with deafness (Brown-Violetta-van laere syndrome)
    ◆ Juvenile onset Als
  – X-linked
    ◆ X-linked bulbospinal neuronopathy (Kennedy’s disease)
  – Autosomal dominant
    ◆ familial Als
secondary motor neuron disorders
• Als-related syndromes
• environmental
  – lead, Arsenic, Mercury, Aluminium, cadmium, Thallium
  – Neurolathirism
  – Konzo
• immune
  – paraproteinemia
  – Dysimmune motor system degeneration, with  
    anti-gM1 antibody
• infective
  – Acute poliomyelitis
  – hiV infection
  – human T-cell leukaemia/lymphoma virus  
    (hTlV-1) infection
  – syphilis
  – Borreliosis
  – prion disease
• Metabolic
  – enzyme defects: hexosaminidase A deficiency
  – endocrine: hyperparathyroidism; hypothyroidism
• physical injury
  – radiation therapy 
  – post-traumatic syringomyelia
• postinfectious
  – post-polio syndrome
• Tumors
  – hodgkin’s disease
  – Non-hodgkin’s lymphoma
• Als plus syndrome (multisystem neurodegenerative  
  disease affecting motor neurons) 
• geographic variants
  – Als-parkinsonism-dementia complex  
    (Western pacific, guam, Kii peninsula) 
• Als and fronto-temporal dementia
• spino cerebellar degeneration
  – Machado-Joseph disease
  – olivopontocerebellar atrophy
• Als and parkinsonism
• Als and multisystem degeneration
  – shy-Dragger syndrome
  – progressive supranuclear palsy
• huntington’s disease
• Neuroacanthocytosis
• prion disease
ic Als (sAls) patients carry a soD1 mutation. Diminished 
disease penetrance is not infrequent for carriers of some 
soD1 gene mutations (like the i113T, g93s, D76Y) and soD1 
mutations can be found in cases of apparently sAls20.
other mutations in other genes have been discovered 
and implicated in Als (Table 10)21.
The remaining ~ 80% of familial cases are linked to as 
yet unknown genes. sporadic Als may possibly be linked 
to alterations in more complex gene systems, forming ge-
netic risks factors rather than a direct cause of Als.
Vesicle-trafficking protein VAPB
recently a mutation in the gene coding for the pro-
tein VApB (vesicle-associated membrane protein-associat-
ed protein B), mapped at 20q13.3, was reported in a large 
white Brazilian family with Als cases and traced to a com-
mon ancestor from the time of contact with portugal. The 
study of VApB and its interactions with other cellular pro-
teins suggests that the mutation may lead to a less stable 
interaction of this endoplasmic reticulum protein with at 
least two other proteins: tubulin and gApDh. These two 
proteins have been previously related to other forms of 
neurodegenerative diseases and are potential key points 
to understand the biology and at which to aim therapeu-
tics. Another involved mechanism is the transport inhibi-
tion of mitochondria affecting the regulation of the an-
terograde motor kinesin-122.
identifying different disease subtypes is an unavoid-
able step toward the understanding of the physiopatholo-
gy of Als and will hopefully help to design specific treat-
ments for each subset of patients23.
NEUROPATHOLOGY
Macroscopic appearances 
The anterior nerve roots often appear shrunken and 
grey when compared with the posterior, sensory roots. The 
spinal cord may be atrophic. in most instances the brain is 
macroscopically normal, but in small proportion of cases 
the precentral gyrus appears atrophic. in patients with de-
mentia the frontal and temporal lobes may be atrophied.
Microscopic appearances 
The most characteristic finding is a loss of motor neu-
rons and astrocytosis in the spinal cord, brain stem, and 
motor cortex. The remaining motor neurons in the spinal 
cord and brain stem may show cytoskeletal abnormalities.
inclusion bodies may be seen in sections stained with 
haematoxylin and eosin, but the distinct inclusions are 
more readily visualized by immunostaining for ubiquitin. 
inclusions are seen in both sporadic and familial Als.
spinal motor neurons may be ballooned due to an ac-
cumulation of phosphorylated neurofilaments, but this is 
a non-specific finding24.
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Table 10. Loci / genes identified in familial ALS / MND.
Disease inheritance locus gene
Als 1 AD / Ar 21q22.21 soD1
Als3 AD 18q21
Als6 AD 16q12
Als7 AD 20ptel
Juvenile Als (Als2) Ar 2q33
Juvenile Als (Als4) AD 9q34
Juvenile Als (Als5) Ar 15q15-22
Als with fTD AD 9q21-22
Als with D/p AD 17q21.11 Tau
Kennedy disease Xr Xq11-Xq12 Androgen receptor
Als: amyotrophic lateral sclerosis; fTD: fronto temporal dementia; D/p: dementia and parkinsonism; AD: autosomal 
dominant; Ar: autosomal recessive; Xr: X-linked recessive; soD1: superoxide dismutase.
PATHOGENESIS
No period of medicine has been without controversy 
and the nineteenth century was no exception. After mo-
tor neuron disease was recognized, Duchenne believed for 
several years that the aetiology of the process was in the 
muscles. cruveiller stated that it was of neural origin. The 
followers of leyden (german scholl) and charcot (french 
scholl) argued over the role of white matter versus mo-
tor neuron. charcot placed emphasis on lesions of nerve 
cells, while leyden contended that all cases of both pBp 
and sMA had lesions of the white matter.
since its description by charcot, more than 130 years 
ago, the pathogenesis of selective motor neuron degen-
eration in amyotrophic lateral sclerosis remains unsolved. 
over the last 20 years, and the past ten years in partic-
ular, our understanding of cellular changes in nerve cells 
has expanded enormously. This increase in knowledge oc-
curred because of advances in neurochemistry and as so-
phisticated experimental techniques became available. 
Two important steps were the discovery of mutations of 
the super oxide dismutase gene for same cases of famil-
ial Als and the ability to make transgenic mouse mod-
el of MND.
over the years, many pathogenic mechanisms have 
been proposed and the multitude of contributing factors 
indicates that Als is a complex disease and also suggests 
that it is a multifactorial disorder. Amongst others these 
include: oxidative stress, excitotoxicity mediated by gluta-
mate, toxic effects caused by the mutation of super oxide 
dismutase1, inclusion of the abnormal protein aggregation, 
intermediaries filaments disorganization, changing the an-
terograde and retrograde axonal transport, microglial ac-
tivation, inflammation, and growth factor deficiency25,26. 
genetic factors, changes in intracellular calcium levels in 
motor neurons, and programmed cell death (apoptosis) 
have also been linked to the development of Als27,28.
As all roads lead to the proverbial rome, we discuss 
here how distinct molecular pathways may converge to 
the same final result that is motor neuron death. recent 
research has provided many hypotheses to explain the 
selective degeneration of motor neurons29. lower motor 
neurons in the brain stem or spinal cord innervate multi-
ple muscle fibers through length axons. These motor units 
may differ in size but all share a similar organization. once 
damaged, motor neurons can not regenerate. As a con-
sequence, denervated muscle fibers can only be reinner-
vated by nearby axon branches of surviving motor neu-
rons. With ongoing disease the balance between dener-
vation and reinnervation will shift towards denervation. 
The time course of this process determines progression 
of disease (fig 1).
Excitotoxicity 
is not the newest and most spectacular hypothesis 
in the Als field, but it is undoubtedly one of the most 
robust pathogenic mechanisms supported by an impres-
sive amount of evidence. excitotoxicity is the patholog-
ical process by which nerve cells are damaged and killed 
by glutamate and similar substances. 
After its release from synaptic terminals, glutamate 
activates three different receptor subtypes in postsyn-
aptic neurons: N-methyl-d-aspartate (NMDA) receptors; 
non-NMDA receptors, sensitive to α-amino3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMpA) and kain-
ic acid; and metabotropic receptors. Activation of non-
NMDA receptors induces the influx of sodium ions and 
the subsequent depolarization of the plasma membrane, 
promoting the extrusion of the magnesium ion normal-
ly blocking the NMDA receptor channel. once the mag-
nesium ion is extruded, binding of glutamate and its co-
agonist, glycine, to their respective sites fully activates 
NMDA-receptors, allowing the influx of sodium and ca2+ 
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Fig 1. Schematic representation of various stages in chronic process 
of denervation and reinervation. (1.1) Three motor units, two type 1 
units (white) and one type 2 (black). The muscle fibers assume a mo-
saic pattern (type 1 muscle fibers surrounded by type 2 muscle fi-
bers). (1.2) Partial loss of motor neuron leads to muscle fiber atro-
phy secondary to denervation. (1.3) Successful reinervation by col-
lateral sprouts from a nearby intramuscular axon. The mosaic pat-
tern is replaced in part by a group of histochemistry uniform type fi-
bers (type grouping). (1.4) The enlarged motor unit is denervated, re-
sulting in a group of histochemistry uniform atrophic muscle fibers 
(neurogenic amyotrophy)30.
ions into the cell. Metabotropic receptors are coupled 
to g-proteins and induce the activation of second mes-
senger systems such as inositol-3-phosphate (ip-3), trig-
gering the release of ca2+ from the endoplasmic retic-
ulum. The extra cellular concentration of glutamate is 
highly regulated through specific Na+-dependent high af-
finity transporters (neuronal excitatory amino acid car-
rier – eAAc1; glutamate-aspartate transporter – glAsT; 
glutamate transporter 1 – glT-1; excitatory amino acid 
transporter – eAAT) located both in neurons and glial 
cells. glutamate taken up by glial cells is metabolized 
to glutamine, which in turn is released to the extra cel-
lular space and taken up by neurons, where it is again 
converted to glutamate to replenish the neurotransmit-
ter pool homeostasis of glutamatergic neurotransmis-
sion depends on the coordinated activity of its different 
components, and failure in any one of them can lead to 
excitotoxic neuronal damage. impairment of glutamate 
removal after its synaptic release leads to the accumu-
lation of the amino acid in the synaptic cleft. The subse-
quent sustained activation of glutamate receptors may 
trigger excitotoxic neuronal death, in particular during 
ATp limiting conditions (fig 2).
Protein misfolding 
Diseases result from the toxicity associated with the 
conversion of the native state of a protein into a patho-
logically misfolded conformation induced by mutation 
and/or environmental triggers. in 20% of familial amy-
otrophic lateral sclerosis mutations in super oxide dis-
mutase cause the protein to misfold and form intracellu-
lar inclusions. Toxicity of these cytoplasmic aggregates is 
thought to arise from aberrant interactions with the pro-
tein-folding chaperone system or from inhibition of pro-
teasomes. Toxicity has also been proposed to result from 
aberrant interactions with mitochondrial proteins such 
as Tom20 or Bcl-2 because soD1 has been detected in 
mitochondria from the spinal cord and brain, and mito-
chondrial vacuolization is an early event in Als models.
Neurofilaments (NFs)
Are the most abundant cytoskeletal component 
of motor axons. They are made of Nf subunit proteins 
whose expression levels must be tightly coordinated to 
maintain neuronal homeostasis; imbalances in this ex-
pression can lead to aggregation of Nfs, a hallmark of 
Als. Nf expression is controlled not only transcription-
ally, but also post-transcriptionally. recent studies have 
implicated aberrant post-transcriptional regulation as a 
likely contributing factor to the neurodegenerative dis-
ease process.
Protein aggregation 
is a pathological hallmark of many neurodegener-
ative diseases, including Als. Whether aggregation is 
a cause or a consequence of disease is fiercely debat-
ed, and this debate is fuelled by evidence both for and 
against the toxicity of protein aggregates32. protein ag-
gregation can result from intrinsic factors such as chang-
es in protein thermodynamic stability, charge, the pro-
pensity to form α-helices and β-sheets, and hydropho-
bicity. recent studies have developed algorithms that 
predict how a given mutation affects protein aggrega-
tion rates33 and have demonstrated that in vitro protein 
aggregation rates depend upon physicochemical proper-
ties, specifically changes in charge, hydrophobicity, and 
secondary structure.
Basic Fibroblast Growth Factor (bFGF) and 
Insulin-like Growth Factor-1 (IGF-1) 
Are trophic factors for motor neurons and glia. in 
neurodegenerative disease, unbalance between neu-
rotrophic and neurotoxic factors ultimately causes mo-
Arq Neuropsiquiatr 2009;67(3-A)
 759
Amyotrophic lateral sclerosis
oliveira and pereira
Fig 2. Glutamatergic neurotransmission and the excitotoxic cell death cascade. Depolarization of the presynaptic terminal af-
ter the arrival of the synaptic potential induces the influx of calcium and the fusion of vesicles, releasing glutamate to the 
synaptic cleft. Glutamate activates AMPA receptors on the post-synaptic neuron inducing the influx of sodium and the depo-
larization of the plasma membrane. The release of magnesium normally blocking the NMDA receptor, leads to its activation 
and to the influx of calcium into the cell. Glutamate is eliminated from the extracellular medium by specific proteins locat-
ed both in astrocytes (GLT-1 and GLAST) and in neurons (EAAC1). Glutamate is metabolized to glutamine in glial cells by glu-
tamine synthetase (GS), which is then release and taken up by neurons. Altered glutamate uptake induces glutamate accumu-
lation, which might result in cell death. Massive calcium influx during NMDA receptors over activation stimulates the activi-
ty of diverse enzymes targeting essential components of the cell. Calcium also induces the production of reactive oxygen spe-
cies, mitochondrial failure and oxidative damage to lipids, proteins and DNA. Mitochondrial dysfunction might disrupt ATP 
production contributing to cell death)31.
tor neuron cell death (by a direct effect and/or by ac-
tivating gliocytes which in turn might initiate apoptotic 
pathways in motor neurons themselves). functional ab-
normalities in the regulation of angiogenic abnormalities 
in the regulation of angiogenic factors (pge-2 / Vegf 
and Angiopoietin-2 / Vegf - vascular endothelial growth 
factor) during hypoxia could be implicated in motor neu-
ron degeneration. This could be relevant during Als pro-
gression since acute intermittent hypoxia frequently oc-
curs particularly due to diaphragmatic failure.
Mitochondrial damage 
in the course of motor neuron degeneration in amy-
otrophic lateral sclerosis and mutant soD1 transgenic 
animal models of familial Als has been demonstrated 
in recent studies. 
Apoptosis 
is the cell death caused by structural or intracellular 
metabolic disorders, and the mark of many neurodegen-
erative diseases such as Als, Alzheimer and parkinson dis-
eases. it is very important to note the variety phenotypic 
involving the motor neuron disease, with typical findings. 
clinical presentations of Als and their prognoses, as the 
form distal in limbs and bulbar, are well known, howev-
er, knowledge of specific forms such as brachial paraple-
gia or “flail arm syndrome”, monomelic atrophy of hiraya-
ma, progressive muscular atrophy, hereditary motor neu-
ronopathy (hMN), provides the link between databases 
and molecular pathogenesis, increasingly known through 
research, which has contributed to the knowledge of spe-
cific mechanisms of cellular apoptosis involving the Als 
(figs 3 and 4).
DNA damage triggers apoptosis by accumulation and 
transcriptional activation of the tumour-supressor pro-
tein p53 that occurs rapidly in response to a wide variety 
of insults including DNA damage, oxidative stress, met-
abolic compromise or excitotoxicity. Depending on the 
initial stress stimulus activation of p53 occurs via various 
pathways that may interact each other upstream of p53 
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activation. p53 exerts its deadly function by transactiva-
tion of pro-apoptotic target genes pUMA (p53-upregulat-
ed modulator of apoptosis) and NoXA, which translocate 
to mitochondria where they mediate disruption of the mi-
tochondria membrane potential and release of apoptot-
ic factors including cytocrome c. Many other transcrip-
tional targets such as peg3/pwl, siah-1 and siVA act in a 
similar way by interacting with pro-apoptotic members 
of the Bcl-2 family at the level of mitochondria. in ad-
dition, p53 may promote cell death via transactivation of 
the death receptor fas or upregulation of ApAf-1 (apop-
totic-protease-activating factor 1) which promotes cas-
pase-dependent apoptosis after formation of the apop-
tosome with cytocrome c and caspase-9. p53 can direct-
ly trigger apoptosis after translocation to mitochondria, 
a process that can occur in synapses (synaptic apoptosis) 
and may involve interactions with BAX or Bcl-xl (Bcl-2-
associated X protein). DNA-damage-induced apoptosis is 
also inhibited by loss of BiM (B-cell lymphoma 2 (Bcl-2) 
-interacting mediator of cell death), but how DNA dam-
age activates BiM is not clear. glucocorticoids kill lym-
phocytes by a mechanism that requires pUMA and BiM. 
how pUMA and BiM are activated by glucocorticoids is 
not yet clear, but it is probable that the glucocorticoid re-
ceptor is involved. cytokine withdrawal kills haematopoi-
etic and neuronal cells by a BiM-dependent and/or pU-
MA-dependent mechanism. hrK (harakiri) has a role in 
growth-factor-withdrawal-induced cell death of certain 
neuronal populations, and BAD (Bcl-2-antagonist of cell 
death) seems to have a minor role in this process in hae-
matopoietic cells, mammary epithelial cells and fibro-
blasts. Antigen-receptor crosslinking triggers apoptosis 
of B and T cells in a BiM-dependent manner. BiK (Bcl-
2-interacting killer) was shown to be activated by B-cell 
receptor (Bcr) crosslinking in human B cells, but no de-
fect in Bcr-stimulation-induced apoptosis was observed 
in Bik–/– mice. BiD (Bcl-2-homology domain 3 (Bh3)-in-
teracting-domain death agonist) is activated by caspase-8-
mediated proteolysis in response to death-receptor stim-
ulation, and this is crucial for this apoptotic pathway in 
hepatocytes but not in lymphoid cells. BMf (Bcl-2-mod-
ifying factor) is activated by loss of cell attachment (also 
known as anoikis), but it is not yet clear whether BMf is 
essential for the execution of this apoptotic stimulus. 
A neuroprotective role for the DNA repair enzyme 
DNA-dependent protein kinase (DNA-pK) in neurons has 
been described. Neurons lacking DNA-pK were highly sus-
ceptible to various insults in vitro and in vivo, exposing 
DNA repair as an essential mechanism of endogenous sur-
vival signaling. Using the p53 inhibitor pifithrin-alpha (pfT) 
Fig 3. Death receptor and intrinsic pathways of apoptosis. Intrinsic pathway is mediated by mitochondrial and the endoplas-
mic reticulum pathways. Distinct initiator caspases are activated in each pathway of apoptosis34.
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and other newly synthesized analogues it was been pos-
sible to demonstrate the essential role of p53 in various 
in vitro and in vivo models relevant to neurodegenerative 
disorders. The latest results exposed reversible inhibition 
of p53 as a promising therapeutic strategy in neurologi-
cal disorders, because p53 inhibitors block the apoptot-
ic cascade and concomitantly enhance endogenous pro-
tective signaling through Nf-kB, even if administered up 
to 6 h after ischemia or brain trauma36.
Involvement of the immune system
complement deposition, anti-neuronal antibodies 
and increased incidence of lympho-proliferative disor-
ders in sporadic Als patients support the hypothesis of 
involvement of the immune system, possibly as a second-
ary event37. Transgenic mouse studies indicate that micro-
glial activation precedes astrocytosis and neuronal loss in 
the spinal cord.
Microglia activation
one of the most studied hypotheses is the putative 
role of the inflammatory response that accompanies mo-
tor neuron death. The proliferation of microglia and as-
trocytes has been considered to be a secondary phenom-
enon, but recently, evidence is accumulating in favor of a 
contributory role of the non-neuronal cell populations to 
the pathogenesis of the disease. in this review, we will in-
troduce the characteristics of microglial cells in the cen-
tral nervous system. We will summarize the evidence of 
the expansion and the activation of the microglial cell 
Fig 4. DNA damage triggers apoptosis by accumulation and transcriptional activation of the tumour-supressor protein p53 
that occurs rapidly in response to a wide variety of insults including DNA damage, oxidative stress, metabolic compro-
mise or excitotoxicity35.
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population that accompanies motor neuron degeneration. 
finally, an overview will be given of the different thera-
peutic strategies that targeted the inflammatory process 
in amyotrophic lateral sclerosis38.
Environmental toxicants 
such as heavy metals, pesticides, and chemicals ap-
pear to be risk factors for sporadic amyotrophic lateral 
sclerosis. even in the familial cases there must be an envi-
ronmental factor that precipitates the onset. An impaired 
ability to break down these toxicants because of differ-
ences in detoxification genes could underlie some cases 
of this disease39. 
cyanobacteria is associated with many neurotox-
ins and cytotoxins including BMAA (β-N-methylamino-
l-alanine), anatoxin, saxitoxin, curacin, microcystins and 
cylindrospermopsin. All of the neurotoxins have targets 
on the central or peripheral nervous system. The ubiq-
uity of cyanobacteria in terrestrial, as well as freshwa-
ter, brackish, and marine environments suggests a poten-
tial for wide-spread human exposure. BMAA, produced by 
symbiotic cyanobacteria present in the cycad roots, was 
first proposed as a contributor to the dementia complex 
(Als/pDc) that has been remarkably prevalent amongst 
the chamorro people of guam. 
BMAA is a non-natural neurotoxic amino acid that be-
comes incorporated into the proteins of higher organ-
isms. protein-bound BMAA has become found in brains 
of chamorros, living in the south pacific island of guam. 
More recently, BMAA has been measured in cohorts of 
caucasian, North American patients dying from sporadic 
Alzheimer’s disease and Als. Although the role of BMAA 
in human degenerative disease is highly debated, there is 
evidence to suggest BMAA may mimic glutamate toxici-
ty and could explain the sporadic unexplained Als cas-
es. however, concerns about the apparent low potency of 
this toxin in relation to estimated levels of human inges-
tion led to doubts about its disease relevance. 
BMAA is transported across the blood-brain-barrier 
via the high affinity saturatable l1 system that carries large 
neutral essential amino acids (leucine, valine, methionine, 
histidine, iso-leucine, tryptophan, phenylalanine, threo-
nine). BMAA has no direct excitatory effects unless the 
exposure was carried out in the presence of bicarbonate. 
When associated to bicarbonate, BMAA assumes a struc-
ture resembling glutamate and capable of activating glu-
tamate receptors, inducing selective motor neurons loss, 
even in lower BMAA concentrations40.
RISK FACTORS
Muscle exercise
Als has been frequently associated with heavy work 
and sport practice in the literature, but data largely re-
main in dispute. studies of sub-groups such as profes-
sional soccer players, marathonians or military veterans 
suggest highly significant odd ratios as high as 20 in fa-
vor of an increased risk to develop Als41.
Soccer link to motor neuron disease 
piazza et al. described an increased incidence of Als 
in italian professional soccer players. They diagnosed 33 
Als cases in a subpopulation of 24,000 soccer players of 
the top three italian divisions from the 1960s to 1996 and 
considered the repetitive brain trauma that soccer play-
ers experience for controlling and advancing the ball with 
their heads as an environmental risk factor for developing 
Als in genetically predisposed individuals42.
other studies have confirmed claims that italian pro-
fessional soccer players have a higher than normal risk of 
developing motor neuron disease. Taioli’study indicates 
that overall mortality and mortality rates from cancer and 
cardiovascular diseases in this population are significant-
ly lower than expected in the general population of the 
same age. however, mortality rates for Als and car acci-
dents are significantly higher than expected, and for Als 
the risk is 18 times than expected43.
Adriano chiò’s team at the University of Turin sur-
veyed the medical records of 7325 professional foot-
ballers who played in italy’s first or second division be-
tween 1970 and 2001. Based on the normal incidence of 
the disease and the players’ ages, the researchers calcu-
lated that there should have been 0.8 cases of Als in this 
group. instead, there were five. The study was prompted 
by what the italian press dubbed “the motor neuron mys-
tery” the discovery a few years ago of 33 cases of Als dur-
ing an investigation of illicit drug use among 24,000 pro 
and semi-pro players in italy. Dubious about the meth-
odology of that initial investigation, chiò’s group applied 
stricter diagnostic criteria to their data, such as only in-
cluding players born in italy. The researchers found that 
the mean age of onset was just 41, 20 years earlier than 
usual, and the longer people play football the greater 
the risk. clusters of cases have been reported in Amer-
ican football, but until now no large-scale studies have 
found any clear link between sport and Als. The cause of 
Als remains unknown, as does the reason for the higher 
rate among footballers. genes undoubtedly contribute, 
but the disease could be triggered by head trauma, per-
formance-enhancing drugs or some other toxin to which 
footballers are exposed. certain viruses are also being in-
vestigated as potential causes44.
LIFETIME OCCUPATION, EDUCATION AND SMOKING 
The univariate analysis done in 364 patients and 392 
controls showed an increased risk of developing Als 
among current cigarette smokers (or=1.7; 95% ci=1.1 to 
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2.6; p=0.01), those with a low level of education (elemen-
tary school) (or=2.2; 95% ci=1.2 to 3.8; p<0.01), and among 
women whose main occupation was classified as crafts 
and related trades workers (or=8.4; 95% ci=1.0 to 70.1; 
p=0.05). Multivariate analysis (with covariates age, smok-
ing, education, and occupation) showed an increased risk 
for current smokers of cigarettes (or=1.6; 95% ci=1.0 to 
2.5; p=0.04). it was concluded that occupation, education, 
and cigarette smoking are risk factors for amyotrophic lat-
eral sclerosis, but only smoking appeared independent-
ly associated45.
GULF WAR VETERANS
A nationwide epidemiologic case ascertainment study 
design was used to ascertain all occurrences of Als for the 
10-year period since August 1990 among active duty mil-
itary and mobilized reserves, including National guard, 
who served during the gulf War (August 2, 1990, through 
July 31, 1991). Among approximately 2.5 million eligible 
military personnel, 107 confirmed cases of Als were iden-
tified for an overall occurrence of 0.43 per 100,000 per-
sons per year. A significant elevated risk of Als occurred 
among all deployed personnel (rr=1.92; 95% cl=1.29, 2.84), 
deployed active duty military (rr=2.15, 95% cl=1.38, 3.36), 
deployed Air force (rr=2.68, 95% cl=1.24, 5.78), and de-
ployed Army (rr=2.04; 95% cl=1.10, 3.77) personnel. ele-
vated, but no significant, risks were observed for deployed 
reserves and National guard (rr=2.50; 95% cl=0.88, 7.07), 
deployed Navy (rr=1.48, 95% cl=0.62, 3.57), and deployed 
Marine corps (rr=1.13; 95% cl=0.27, 4.79) personnel. over-
all, the attributable risk associated with deployment was 
18% (95% cl=4.9%, 29.4%). Military personnel who were 
deployed to the gulf region during the gulf War peri-
od experienced a greater post-war risk of Als than those 
who were not deployed to the gulf46.
PROGNOSTIC FACTORS
A systematic review to summarize current knowledge 
concerning factors related to survival in Als and to eval-
uate the implications of these data for clinical trials de-
sign was done by chiò e colleagues. The median survival 
time from onset to death ranges from 20 to 48 months, 
but 10–20% of Als patients have a survival longer than 10 
years. older age and bulbar onset are consistently report-
ed to have a worse outcome. There are conflicting data on 
gender, diagnostic delay and el escorial criteria. The rate 
of symptom progression was revealed to be an indepen-
dent prognostic factor. psychosocial factors, fTD, nutri-
tional status, and respiratory function are also related to 
Als outcome. The effect of enteric nutrition on surviv-
al is still unclear, while NippV has been found to improve 
survival. There are no well established biological mark-
ers of progression, although some are likely to emerge in 
the near future. These findings have relevant implications 
for the design of future trials. randomization, besides the 
type of onset, should take into account age, respiratory 
status at entry, and a measure of disease progression pre-
entry. Alternative trial designs can include the use of nat-
ural history controls, the so-called minimization method 
for treatment allocation, and the futility approach47.
in other study to identify prognostic factors for sur-
vival in Als, performed in france, a cohort of 2069 pa-
tients fulfilling broad entry criteria treated with riluzole, 
included a over 100 demographic, biological, clinical and 
quality-of-life variables were monitored and assessed for 
their effect on survival. Thirteen variables were found to 
affect survival independently and were used to construct 
a survival prediction score, rl401. These included age, dis-
ease duration, slow vital capacity, intensity of tiredness 
(visual analogue scale), number of body levels with spas-
ticity, atrophy and/or fasciculations, cough, distal mus-
cle strength, household income, depression and two bio-
logical parameters, plasma creatinine levels and neutro-
phil counts. A simplified score, rl401s, was constructed, 
designed to be easy to use and interpret. The predictive 
powers of the two scores were similar48.
ELECTROPHYSIOLOGY, IMAGING AND  
MARKERS OF DISEASE PROGRESSION
There are no current diagnostic tests for Als or surro-
gate markers of disease progression. surrogate markers of 
Als disease progression would be valuable measurements 
for drug efficacy in clinical trials and also to identify new 
targets for drug therapy. 
CLINICAL ELECTROPHYSIOLOGY 
A consensus meeting (consensus of an international 
symposium sponsored by ifcN), December 3–5, 2006, in 
Awaji-shima, Japan) was held to determine the best use 
and interpretation of electrophysiological data in the 
diagnosis of Als. The utility of needle eMg and nerve 
conduction studies was affirmed. it is recommended 
that electrophysiological evidence for chronic neuro-
genic change should be taken as equivalent to clinical 
information in the recognition of involvement of indi-
vidual muscles in a limb. in addition, in the context of a 
suspected clinical diagnosis of Als, fasciculation poten-
tials should be taken as equivalent to fibrillation poten-
tial and positive sharp waves in recognising denervation. 
The importance of searching for instability in fascicula-
tions potentials and in motor unit potentials in Als is 
stressed. These changes in the interpretation of electro-
physiological data render obsolete the category proba-
ble laboratory-supported Als in the modified el escori-
al diagnostic criteria for Als49.
gutierrez et al.50 demonstrate that, in early stage of 
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Als, distal muscles are more affected tan axial and prox-
imal muscles. fasciculation, fibrillation, psW, reinervation 
potentials and decreased recruitment patterns were sig-
nificantly more frequent and severe in distal limb mus-
cles, especially in upper limbs, than in their correspond-
ing axial and proximal muscles. The most affected items 
of the Alsfrs were those related to fine hand move-
ments (handwriting, cutting food) and language. There 
was significant correlation between electrophysiological 
and functional involvement of hand muscles. items re-
lated to gross movements (climbing stairs, walking, turn-
ing in bed) and dependent on proximal and axial mus-
cles, were relatively preserved at this stage of the dis-
ease. Median nerve distal latencies (both motor and sen-
sory) and motor conduction velocity (elbow-wrist) were 
affected in 52% of the patients, despite normal ampli-
tude of the responses.
clinical neurophysiological techniques, including 
Neurophysiological index, motor unit counting methods 
(MUNe), and transcranial magnetic motor cortex stimu-
lation appear to be useful in measuring change in clinical 
trials in Als. MUNe, M-wave amplitude and the Neuro-
physiological index are sufficiently reliable, sensitive, and 
relevant to the clinical problem of Als, to be used in clin-
ical trials in the disease. Transcranial magnetic stimula-
tion is of limited value, but a combination of the measure-
ments made as part of this technique may also be useful51.
IMAGING
Methods for detection of upper motor neuron abnor-
mality appear sensitive but require further study, partic-
ularly regarding their value when clinical signs of upper 
motor neuron lesion are uncertain.
proton magnetic resonance spectroscopic imaging 
(Mrsi) can non-invasively detect neuronal loss or dys-
function by demonstrating a low signal from the neuronal 
marker N-acetylaspartate (NAA) relative to creatine (cr) 
or choline (cho). previous studies have demonstrated de-
creased NAA/cr in the motor cortex of Als patients.
Diffusion tensor (DT) Mri imaging is a quantitative Mri 
technique. DT Mri allows the measurement of quantities 
reflecting the size, such as the apparent diffusion coeffi-
cient (ADc) and orientation such as fractional anisotro-
py (fA) of water- filled spaces in biological tissues. com-
pared to controls, Als patients had significantly lower fA 
(pv0.01) in posterior limb of internal capsule, cerebral pe-
duncle, corticospinal tract (csT) and corticobulbar tract. 
ADc values of Als patients were significantly higher than 
those of controls in posterior limb of internal capsule, 
cerebral peduncle, csT and corticobulbar tract. finally, a 
significant correlation was found between fA values and 
the Alsfrs-r. ADc values were inversely correlated with 
the disease severity52. 
BIOMARKERS
research is also needed in order to identify protein 
biomarkers that correlate to clinical measurements of 
Als and disease progression. Disease biomarkers provide 
a more effective therapy, since pharmacotherapy is most 
beneficial when given early in the course of MND.
CEREBROSPINAL FLUID
cerebrospinal fluid (csf) is a promising source of bio-
markers in amyotrophic lateral sclerosis (Als):
Levels of neurofilament light (NF-L) protein
A marker of axonal degeneration, might provide diag-
nostic and prognostic information on the disease. A study 
including 60 sporadic and 19 familial Als patients, 206 ref-
erence patients with other neurological disorders and 40 
age- and sex-matched healthy controls showed that csf 
levels of Nf-l. concentration [median (range)] was strong-
ly elevated in Als [2110 (255-10 800) ng/l] compared with 
reference patients and healthy controls [277 (<125-15 506) 
and 175 (<125–710) ng/l, respectively, p<0.001] and corre-
lated inversely with disease duration (spearman r= –0.518, 
p=0.001)53.
Cystatin C protein, phosphor-neurofilament 
H and anti-thrombin III protein
A prospectively collected csf and blood plasma ev-
ery 4 months was performed in 24 Als patients and 14 
control subjects over a 2-year time frame. The data indi-
cates that cystatin c protein may have utility as a surro-
gate biomarker and could differentiate fast versus slow 
progression (levels in both the csf and plasma decrease 
over time in Als patients that exhibit rapid clinical dis-
ease progression. in addition, phosphor-neurofilament h 
and anti-thrombin iii protein levels were also altered (in-
creased levels) during Als disease progression54.
Proteome analysis
Using the two-dimensional difference in gel electro-
phoresis (2-D-Dige), csf samples from patients with Als 
(n=14) were compared with those from normal controls 
(n=14). protein spots that showed significant differences 
between patients and controls were selected for further 
analysis by MAlDi-Tof mass spectrometry. The identified 
proteins, two were upregulated and three were down-reg-
ulated in csf in Als. of these, two proteins (Zn-alpha-2-
glycoprotein and ceruloplasmin precursor protein) have 
not been reported in csf of patients with Als so far. in 
contrast, several other proteins (transferrin, alpha-1-anti-
trypsin precursor and beta-2-microglobulin) seem to be 
unspecifically affected in different neurological diseases 
and may therefore be of limited value as disease-related 
biochemical markers in Als55.
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DIFFERENTIAL DIAGNOSIS
it is now recognized that incorrect diagnosis of Als is a 
significant problem, and several studies over the past two 
decades have collected data indicating that rates of mis-
diagnosis in the general medical population are high56-59. 
The diseases that more commonly cause a diagnostic di-
lemma are wide (Table 11).
The adult-onset spinal muscular atrophies, which en-
compass a very broad range of primary motor neuron dis-
ease, have been classified either by pattern of inheritance, 
distribution of weakness, or age of onset (Table 12).
IMPORTANT CLINICAL CHARACTERISTICS
Cognitive and psychological change
Als was traditionally thought to affect solely the 
lower motor neurons and corticospinal tracts, with the 
mind and senses remaining intact. indeed, much of the 
patient literature and information in medical textbooks 
continues to promote this myth. recent studies suggest 
that the pathogenic processes of Als are more extensive, 
involving dysfunction of cortical grey and white matter 
with clinical correlates of impairment in cognition and 
language. in reality, at least a subgroup of Als patients 
experience personality changes and cognitive problems 
consistent with fronto-temporal dementia (Als-fTD). 
Neuropsychological, neuropathology, and more recent-
ly genetic studies have started to unravel an underlying 
shared mechanism beneath Als and fTD. Until recent-
ly cognitive deterioration was associated almost exclu-
sively with a subgroup of 3–5% Als patients with fronto-
temporal dementia. however, a number of neuropsycho-
logical investigations including the cambridge Behavior-
al inventory (cBi) have been used to help detect the be-
havioral and neuropsychiatry manifestations of fTDys60 
Table 11. Diseases that more commonly cause a diagnostic 
dilemma with ALS /MND.
With UMN signs
• hereditary spastic paraparesis
• hTlV-1-associated myelopathy
• Multiple sclerosis
• stroke syndrome with spastic hemiparesis
• Toxic spastic paraparesis: caused by ingested foodstuff toxins
  – lathyrism (derived from the chickling pea vetch 
    containing-β oxalil-l-aminoacid)
  – Konzo (due to toxic cyanogenic cassava)
With lMN signs
• other motor neuronopathies
  – Adult-onset spinal muscular atrophies
  – post-polio syndrome
• compressive radiculopathy: cervical; lumbosacral
• entities with fasciculation
  – Benign fasciculations   
  – Diseases of motor root, plexus and peripheral nerve
• Mononeuropathy
  – entrapment
  – Mononeuropathy multiplex
• Multifocal motor neuropathy with or without conduction block
• plexopathy
  – Brachial plexus neuropathy 
  – Diabetic amyotrophy
  – Neurogenic thoracic outlet syndrome
• polyneuropathy
  – endocrine polineuropathy: Diabetes
  – hereditary motor and sensory neuropathy (charcot-Marie- 
    Tooth)
  – infectious polyneuropathy: lyme, hiV
  – Motor variant of chronic inflammatory demyelinating 
     neuropathy
  – Toxic polineuropathy: heavy metals
• Neuromuscular junction defect
  – Myasthenia gravis
  – Myasthenic syndrome
• Myopathy
  – Distal myopathy
  – inclusion body myositis
  – polymiositis
With combination of UMN and lMN
• cervical spondylosis with myelopathy and radiculopathy
• syringomyelia
• hiV infection (Aids)
• spirochetal infections: syphilis; lyme disease
• Adrenomyeloneuropathy
• Adult polyglucosan body disease
• organophosphate toxic neuropathy
• central neurofibromatosis
With bulbar symptoms
• structural brain lesion: tumour; stroke
• pseudo bulbar palsy
• syringobulbia
• Myasthenia gravis 
Table 12. Adult-onset spinal muscular atrophies.
proximal predominance
• spinal muscular atrophy
segmental spinal muscular atrophy
• flail arm syndrome
• flail leg syndrome
• Monomelic atrophy (hirayama syndrome)
spinal-bulbar
• Kennedy’s disease
scapuloperoneal
Distal predominance
Asymmetric or unclassifiable
other diseases that must be included in the list of differential 
diagnosis of Als:
• Machado-Joseph disease
• celiac disease
Arq Neuropsiquiatr 2009;67(3-A)
766
Amyotrophic lateral sclerosis
oliveira and pereira
recently demonstrated selective impairments in execu-
tive and memory function in no demented Als patients 
in higher proportion (25–75%).
Although the cause(s) of this process remain to be de-
fined, as with the clinical heterogeneity, there is likely to 
be significant biochemical heterogeneity. This includes al-
terations in tau protein metabolism which are present in 
a proportion of familial and sporadic Als cases, as well 
as the western pacific variant, and recently described al-
terations in the metabolism of the TAr DNA binding pro-
tein 43 (TDp-43)61.
ANIMAL MODELS
The neuropathological results obtained from human 
Als autopsy cases are valuable and important to under-
stand Als. however, almost all of such cases represent 
only the terminal stage. This makes it difficult to clari-
fy how and why Als motor neurons are impaired at each 
clinical stage from disease onset to death, and as a con-
sequence, human autopsy cases alone yield little insight 
into potential therapies for Als. 
The development of small animal models is of major 
interest to unravel the etiology, pathogenesis and treat-
ment of neurodegenerative diseases, including Als. Al-
though animal models cannot replicate human Als, in or-
der to compensate for the shortcomings of studies using 
human Als autopsy samples, researchers must inevitably 
rely on Als animal models that can yield very important 
information for clarifying the pathogenesis of Als in hu-
mans and for the establishment of reliable therapy. great 
hopes were put into transgenic mouse models of Als in 
which mutant forms of soD-1 found in familial forms of 
Als were over expressed62. of course, human Als and all 
Als animal models share one most important similarity 
in that both exhibit motor neuron degeneration/death. 
This important point of similarity has shed much light on 
the path mechanisms of the motor neuron degeneration/
death at the cellular and molecular levels that would not 
have been appreciated if only human Als autopsy sam-
ples had been available63.
Transgenic mice expressing mutant forms of soD1 
gene serve as models of the familial form of Als and has 
been very useful to study the initial mechanisms under-
lying this neurodegenerative disease. several hypotheses 
have been advanced to explain the selective loss of mo-
tor neurons such as apoptosis, neurofilament disorgani-
zation, oxidative stress, mitochondrial dysfunction, astro-
gliosis and excitotoxicity. Although disease onset appears 
at adulthood, recent studies have detected abnormali-
ties during embryonic and postnatal maturation in ani-
mal models of Als. 
Murine models of Als have been useful tools to in-
vestigate the effects and mechanisms of drug actions. 
At present, the most frequently used model to evaluate 
candidate drugs is the g93A soD-1 mouse. ongoing or 
planned trials are exploring the value of antiglutamater-
gic drugs, antioxidants, neurotrophic factors, anti-inflam-
matory drugs and anti-aggregation drugs.
THERAPEUTIC APPROACHES
Although amyotrophic lateral sclerosis and its variants 
are readily recognized by neurologists, about 10% of pa-
tients are misdiagnosed, and delays in diagnosis are com-
mon. prompt diagnosis, sensitive communication of the 
diagnosis, the involvement of the patient and their fami-
ly, and a positive care plan are prerequisites for good clin-
ical management64.
Treatment starts with an early and efficient diagno-
sis. in the past, many clinicians believed that there was no 
reason to make an early diagnosis because there was lit-
tle to offer the patient with Als. however, development 
over the past two decades has changed the way to face 
Als. first, an efficient diagnosis evaluation reduces un-
certainty for the patient and prevents a long wait for ex-
clusionary tests to be performed. second, it saves money 
and time. Third, patients and caregivers benefit from ear-
ly referral to Als speciality clinics. fourth, and most im-
portant, there is growing evidence that early intervention 
can improve and prolong life65,66.
Communicating the diagnosis 
communicating the diagnosis of Als in an empathetic 
fashion is a most important and sensitive step in disease 
management. The information process can not be stan-
dardized, which implies that the individual approach is 
to be preferred. content and possible modes of delivery 
information to Als patients and their families have been 
constantly reviewed and are only briefly summarized here.
What they already know – With the internet and other 
medicine information, it is common, in industrial coun-
tries, an idea that what some symptoms represent. it is 
usually best to start by finding out what the patient al-
ready knows or suspects and how much more he/she 
wants to know. 
What to tell – Minimal information should include the 
name and the progressive nature of the disease with an 
emphasis on positive aspects. early discussion of progno-
sis should stress physician-patient relationship. Available 
therapies, unconventional measures, palliative measures 
should be mentioned, together with their realistic expec-
tations and known side effects. current research should 
be mentioned to foster hope. information on Als patient 
associations is of great importance.
How to tell – communication should take place in a qui-
et, private room without interruptions, and in the pres-
ence of the family. According to Maguire et al.67 three un-
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derlying objectives in the information should be follow: a) 
do not withhold information if the patient wants it; b) do 
not impose information if the patient does not want it; c) 
gauge and respond to the patient’s reaction to the news.
Reinforcement of information – Written material on the 
disease, a letter summarizing the consultation in lay terms, 
and/or a tape recording of the conversation is useful. 
it may intuitive that initiation of treatment early in the 
course of Als, when there are more motor neurons avail-
able that may benefit from therapeutic intervention, will 
be more beneficial than starting treatment a latter time. 
Treatment is directed to saving the vulnerable neurons. 
Als/MND therapeutics will require juxtaposition in the 
patient of: primary treatments to mitigate the underlying 
pathogenesis of Als/MND; Adjuvant treatments to stop 
propagating events trying to maximize survival, strength 
and function; symptomatic treatments to minimize 
symptoms and complications resulting from Als/MND. 
GIVING A TREATMENT
The complex pathophysiology of Als presents many 
potential therapeutic targets, and a number of novel 
pharmacological agents with varying mechanisms of ac-
tion have been tested clinically, including agents target-
ing excitotoxicity, neurotrophic agents, immunomodu-
lators, agents targeting oxidative stress, anti-apoptot-
ic compounds and nutritional supplements. By virtue of 
the very rapidly developing disease course, Als is also of-
ten regarded as medical condition suited to proof of con-
cept testing for compounds with anti-neurodegenerative 
potential. over 500 products have been investigated for 
neuroprotective effects including those from the cate-
gories of free radical scavengers, anti-excitotoxic agents, 
apoptosis (programmed cell death) inhibitor, anti-inflam-
matory agents, neurotrophin factor, metal ion chelator, 
ion channel modulator and gene therapy (Table 13)68,69.
Animal drug-screening study in Als is one of the most 
important steps to test a potential useful treatment. Al-
most exclusively the mutant soD1g93A mouse is utilized, 
permitting identify neuroprotective agents that could 
mitigate the underlying pathogenesis of Als/MND.
Although the many candidates were shown to be ef-
fective in mice, the ability of this model to predict drug 
efficacy in humans is ambiguous. several drugs that pro-
long survival in animal studies have not shown efficacy in 
human clinical trials. 
 
THERAPEUTIC TRIALS
The 1970s saw the beginning of a greater interest in 
clinical trials for Als/MND. clinical trials are imperative 
to find effective medications for Als and have significant-
ly evolved over the last decade. New outcome measures 
have been developed that have reduced the sample size 
requirement as compared with survival studies. There has 
been increasing recognition that dose-ranging studies are 
crucial to full evaluation of experimental agents. While 
the requirements of late stage trials have not changed, 
many new designs have been suggested for earlier phase 
development. While no design achieves the perfect bal-
ance of sensitivity and efficiency, clinical trialists continue 
to work toward the goals of smaller and shorter trials so 
that more compounds can be studied concurrently70.
OUTCOME MEASURES FOR  
EARLY PHASE CLINICAL TRIALS
Disease progression has been assessed by different 
outcome measures, including: revised Als functional 
rating scale (Alsfrs-r), Norris Als scales, quality of life 
(short form-36 [sf-36]), pulmonary function (forced vital 
capacity [fVc]) and segmental muscle strength (Medical 
research council [Mrc] scale).
As the number of potential neuroprotective agents for 
Als increases, the need for early phase trials that screen 
drugs before proceeding to efficacy trials also grows. 
however, it is not known which outcome measures per-
form best and also provide the most meaningful informa-
tion in brief small trials. To try to assess the performance 
of different outcome measures for use in early phase clin-
ical trials in Als, thirty patients underwent six monthly 
Alsfrs-r), fVc, Mrc and quality of life. The Alsfrs-r 
most strongly predicted survival and provided the most 
complete data71.
The first large multi-center double-blinded, placebo 
controlled trial took place in the 1990s. Many drug com-
pounds to treat Als/ MND have been tested but failed. 
equivocal results for insulin like growth factor i (igf-1, Myo-
trophin®) were reported in 1990s, one positive and one neg-
ative in double-blind, placebo controlled trials. since them, 
treatment for Als has focused in modulation of glutamate 
toxicity, mitochondrial dysfunction and in the involve-
ment of the immune system in the progress of the disease.
The prerequisites for a successful clinical trial in large 
phase iii efficacy studies are: Drug selection based on dis-
ease causes; Agents already tested in Als animal models 
or clinical trials; Determination if the drug crosses the hu-
man BBB to reach its target ligand, before starting phase 
ii studies; Determination of the pharmacokinetic profile, 
the safety/toxicity properties, and the most efficacious 
dose of the chosen drug in humans, before starting the 
phase iii studies; To identify if the tolerability of a deter-
mined dose in patients with Als is the same of healthy 
patients and safe; To determine if the frequency of ad-
verse events in patients with Als is the same of healthy 
patients and tolerable; Dose-ranging studies are a prereq-
uisite to phase iii studies to determine the most effective 
and safe dosage.
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Table 13. Neuroprotective agents with potential effect on ALS.
• Antiaggregation
  – scriptaid
  – Trehalose
• Anti-apoptosis
  – Activated protein c
  – calpain inhibitors 
  – caspase inhibitors
    ◆ Minocycline
  – clusterin 
  – DNA binding drugs
  – lithium 
  – rasagiline
  – Tch 346
• Antiepileptic drugs
  – levetiracetam
  – Valproic acid
• Anti-excitotoxicity
  – AMpA receptor antagonist
    ◆ Memantine
    ◆ NBQX
    ◆ rpr 119990
  – eAAT2 promoter activity
    ◆ ceftriaxone
  – glutamate carboxypeptidase ii inhibitor: 2-MppA
  – glutamate inhibitor
    ◆ riluzole
    ◆ Talampanel
  – Metabotropic glutamate receptor modulators 
    ◆ cannabinoids
    ◆ Dexanabinol (hU-211) 
    ◆ glutathione
  – NMDA Nr2B subunit receptor antagonists 
    ◆ ifenprodil
    ◆ Magnesium 
    ◆ NAAlADase inhibitors
• chemotherapy
  – cyclosporine A
  – Vincristine
• cupper chelator
  – Trientine
  – d-penicillamine
• gene therapy
  – rNAi-based therapy
• hormones
  – selective estrogen receptor modulators 
  – receptor-independent neuroprotective effects of estrogens
• immunomodulator
  – copaxone/glatiramate 
  – Thalidomide
• ion channel modulators
  – calcium channel blockers
    ◆ Nimodipine.
  – Na+ channel blockers. 
  – Neuroprotective potassium channel inhibitors
• Mitochondria-targeted
  – Arimoclomol
  – glutathione 
  – heat shock proteins
  – hyperbaric oxygen therapy
  – omega-3 fatty acids
  – Vitamine e
• Neurotrophic factors
  – Brain-derived neurotrophic factor (BDNf)
  – ciliary neurotrophic factor (cNTf) 
  – fibroblast growth factors (fgf)
  – glial cell line-derived neurotrophic factor (gcDNf) 
  – insulin-like growth factor (igf) 
  – Nerve growth factor (Ngf)
  – Neurotrophins (NTf)
  – Vascular endothelial growth factor (Vegf)
• Anti-inflamation
  – interleukin-1 antagonists 
  – coX inhibitor
    ◆ celecoxib
    ◆ rofecoxib
    ◆ sulindac
  – protein kinase c inhibitor
    ◆ Tamoxifen
• Antioxidants
  – Aeol 10150
  – co-enzime Q10 
  – lipoic acid
  – N-acetyl-l-cysteine
  – synthetic soD catalase
• cell based therapy
  – Umbilical cord blood cells
  – BM transplant
• Transcranial magnetic stimulation 
  – combination therapy
    ◆ Drugs
      rofecoxib and creatine
      rasagiline and riluzole
      Minocycline, riluzole and nimodipine
    ◆ growth factor and virus
      AAV-cT1
      AAV-gDNf
      AAV-igf
      AVr-gDNf
      lV-Vegf
      Vegf
AAV: adeno-associated-virus; AVr: Adenovirus; 
lV: lentivirus; BM: bone marrow.
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Besides having a large number of drug candidates that 
may be neuroprotective in Als patients, only a small num-
ber has been tested at any one time, as recommended cri-
teria. some drugs showed some efficacy in animal mod-
el, but not in humans with Als (celebrex72,73; creatine74,75; 
gabapentin76,77; acetylcysteine78,79). This discrepancy may 
be due to intraspecies differences (mouse strain, sex, envi-
ronmental factors), in pharmacokinetics and the difficulty 
in establishing dose equivalence to achieve the same bi-
ologic activity in humans as observed in mice. it may also 
be that this mouse model of familial Als does not predict 
drug effect in patients with sporadic Als and that devel-
opment of alternative models should be prioritized.De-
spite initial positive results in some preclinical and ear-
ly clinical studies, large-scale clinical trials with differ-
ent agents have failed to demonstrate a marked effect in 
patients with Als / MND. riluzole is the only one agent 
that has demonstrated a mild but consistent neuropro-
tective action.
RILUZOLE 
riluzole is a benzothiazole derivative that modulates 
glutamatergic activity, thereby suppressing excitotoxicity. 
in 1994, the first study of riluzole (rilutek®), 50 mg, bid, 
was reported80, and the results prolonging patient surviv-
al were confirmed in a larger double-blinded, placebo-
controlled trial that included North American centers81-83. 
great excitement greeted the first positive drug study for 
Als. After demonstrating of decline in mortality, riluzole, 
most likely related to its anti-excitotoxic properties, was 
approved by the United states food and Drug Administra-
tion in December, 1997. later meta-analyses indicate that 
the effect was real, and that there may have been a small 
effect on function. 
Als/MND is one of few neurodegenerative diseases 
which have a treatment [riluzole], albeit limited, reputed-
ly directed at the underlying pathogenesis of the disease, 
that affects the course of survival, rather than merely the 
symptoms, of the disease process. Although this slowing 
of progression by a therapeutic intervention may not be 
large, it represents a breakthrough in the treatment of 
Als, not only clinically but also psychologically.
Antioxidant treatment for ALS / MNd
since the lou gehrig, antioxidants have been system-
atically used in patients with Als. Although, a systemat-
ic review selecting all randomized or quasi-randomized 
controlled trials of antioxidant treatment for Als – co-
chrane Neuromuscular Disease group Trials register (Au-
gust 2005), MeDliNe (January 1966 to August 2005), eM-
BAse (January 1980 to August 2005) and other sources - 
showed insufficient evidence of efficacy of individual an-
tioxidants, or antioxidants in general, in the treatment of 
people with Als. The high tolerance and safety, and rel-
atively low cost of vitamins c and e, and other consider-
ations related to the lack of other effective treatments 
for Als could explain the continuing use of these vitamins 
by physicians and people with Als. While there is no sub-
stantial clinical trial evidence to support their clinical use, 
there is no clear contraindication84.
SUPPORTIVE CARE
The natural course of Als can be defined as death 
from respiratory failure. however, life can be extended 
for many years by artificial ventilation, although death of 
motor neurons continues, and a patient may become to-
tally paralyzed and be effectively “locked in”. 
Management of Als / MND patients can be a day-to-
day struggle. This condition affects every aspect of one’s 
being: physical, emotional, social, financial, and spiritual. 
Adaptation to loss of function will be ongoing process, 
requiring continuous revaluation.
Although effective treatment for Als /MND was not 
available, the feeling that “nothing can be done” for Als 
patients began to change: 
– 1975: “symptomatic care of patients with amyo-
trophic lateral sclerosis “published by smith and Norris; 
– 1980s: “Quality of life” is acknowledged as an inte-
gral aspect of patient care;
– 1980s: books devoted to supportive care emerged;
– 1984: “Motor neuron disease: can we do better” is 
published by Newrick and langton-hewer;
– 1985: “Motor neuron disease: toward better care” 
published by smith and Norris;
– 1990s: ongoing clinical research occurred in the ar-
eas of speech, swallowing, nutrition, exercise, respiratory 
care, emotional well being, quality of life, caregiver bur-
den, and health assessment tools: such as Als function-
al rating scale (Alsfrs –r), Norris limb and Bulbar scale, 
and Appel functional rating scale;
Multidisciplinary health care teams were identified as 
the best approach to Als/MND patient care. in addition, 
consensus-based approaches to specific patient problems 
dominated the literature. 
Today, there are many specialized clinics in North 
America, europe, oceania and orient with multidisci-
plinary teams to guide the patient and family. The clinics 
provide clinical and emotional care, education, support 
groups, newsletters, and various other support services. 
in Brazil, we have seen the same transformation, with the 
creation of multidisciplinary teams.
combination of pharmacotherapy and other thera-
peutic interventions can increase survival, help patients 
strengthen muscles, improve their ability to perform ac-
tivities of daily living (ADl) and optimize their quality of 
life. An understanding of the characteristics of the disease 
Arq Neuropsiquiatr 2009;67(3-A)
770
Amyotrophic lateral sclerosis
oliveira and pereira
and the corresponding treatment modalities is crucial for 
enhancing the patient’s quality of life.
symptomatic treatments, both pharmacological and 
non pharmacological, along with alternative therapies can 
be incorporated into a comprehensive plan of care.
in Als/MND, the rate of progression is unpredictable. 
factors that impact survival can be precipitated by either 
the patient, the health care professional, and/or the pa-
tient’s financial resources. lack of adherence, difficulty in 
decision making, and ineffectual coping mechanisms by 
the patient can be a negative impact. The fragmentation 
of care can be result of inaccessibility to specialized clin-
ics. This along with an inequitable distribution of resourc-
es by some governmental agencies, insurance companies, 
and managed care organization/hMo can lead to poor 
patient outcomes.
early identification of problems and symptom man-
agement is imperative. intervention must be timely- of-
ten they are too late or unplanned (e.g., emergency ven-
tilation). “symptom-specific management plays an impor-
tant part in avoiding costly readmissions for repeat respi-
ratory crisis or injuries from falls. A mechanism for identi-
fying patient problems and monitoring patient outcomes 
must be put in place in order to enhance Als care.
one method by which we can achieve these goals is 
by the development of care pathways. These can reduce 
the possible error of omission by providing guidelines for 
assessment, decision making, communication, interven-
tion, and evaluation of patient care. 
PRINCIPLES OF ALS / MND MANAGEMENT
– patients should make the decisions. it is the care 
team’s responsibility to provide the information in a time-
ly manner;
– The cultural and psychosocial background of the 
patient and family should be considered;
– Als care is best delivered by a multidisciplinary 
team. Most patients do best when they are seen every 
3–4 months; however, visits should be scheduled based 
on rate of disease progression;
– The issue of advanced directives should be raised 
soon after diagnosis. The team must understand that pa-
tients can change their minds and the issue should be re-
visited every 6 months. failure to address the issue can 
precipitate a crisis in which a patient who did not want 
to artificially ventilated is intubated;
– psychosocial needs should be addressed throughout 
the illness. patients living with Als face a series of losses 
and changing needs. fear of abandonment or dying alone 
is common. it is important to protect the patient from the 
loss of self-image and feelings of isolation;
– At each stage of the disease, every effort should be 
made to encourage patients to live as normal lives as pos-
sible, while ensuring that they and their families have ac-
cess to the comprehensive resources that will allow them 
to maintain function, as well as access to emotional and 
spiritual support85.
SYMPTOMS TREATMENT
While Als is an incurable disease, many symptoms are 
amenable to supportive and adjunctive therapies, some of 
which may even improve the disease course. 
Weakness
patients are usually given an exercise program early in 
the course of Als to help delay disability in strong mus-
cles. exercise entails stretching, strengthening and aero-
bic exercises. some studies suggest that the early stag-
es of Als may be prolonged by moderate exercise. pa-
tients that practiced strengthening exercises using weights 
three times a week appeared to maintain function and re-
tain quality of life. eight of the 13 people assigned to the 
weight training completed the six month study, as did ten 
of the 14 who did only stretching exercises. function de-
clined 12 percent less rapidly in the weight training group, 
and quality of life declined 16 percent less rapidly, accord-
ing to the investigators working with Dal Bello-haas86. it 
is reasonable to begin a strengthening program as soon 
as possible after the diagnosis in order to maximize the 
strength of unaffected or mildly affected muscles. 
Spasticity
A systematically review all types of treatments for 
spasticity in Als was conducted by Barnham87. The co-
chrane Neuromuscular Disease group specialised trials 
register (searched January 2003), MeDliNe (January 1966 
to January 2003), eMBAse (January 1980 to January 2003), 
ciNAhl (January 1982 to January 2003), AMeD (January 
1985 to January 2003) and lilAcs (January 1982 to Janu-
ary 2003) for randomized controlled trials were searched. 
There were included quasi-randomized or randomized 
controlled trials of participants with probable or definite 
Als revised criteria. Trials of physical therapy, modalities, 
prescription medications, non-prescription medications, 
chemical neurolysis, surgical interventions, alternative 
therapies were included. The primary outcome measure 
was reduction in spasticity at three months or greater as 
measured by Ashworth The secondary outcome measures 
were: validated measures based on history, physical ex-
amination, physiological measures, measures of function, 
measures of quality of life, serious adverse events, and 
measures of cost. only one randomized controlled trial 
that met the inclusion criteria was identified for this re-
view. The included study was a trial of moderate intensity, 
endurance type exercise versus ‘usual activities’ in 25 pa-
tients with amyotrophic lateral sclerosis. At three months 
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patients performing the 15 minute twice daily exercises 
had significantly less spasticity (mean reduction of 0.43 
Ashworth grades versus an increase of 0.25 in controls), as 
measured by the Ashworth scale. The reviewers conclud-
ed that individualized, moderate intensity, endurance type 
exercises for the trunk and limbs may help to reduce spas-
ticity in motor neuron disease. No other medical, surgical 
or alternative treatment and therapy had been evaluated 
in a randomized fashion in this patient population.
DYSARTHRIA
Dysarthria may occur early in the disease, as a pre-
senting feature, and later become severe in the most of 
patients. With time, some patients become anarthric. in 
pBp, dysarthria generally develops prior to dysphagia, 
with both UMN and lMN degeneration contributing to 
symptoms. UMN speech tends to be slow and effortful, 
with poor enunciation and a harsh, strained quality to the 
voice. lMN in the brainstem may cause slow and effortful 
speech with breathiness of the voice and slurring of con-
sonants. in some, velopharyngeal incompetence causes 
air leakage through the nose and lends a hypernasal qual-
ity to the voice88.
DYSPHAGIA
The most Als patients experience some degree of 
swallowing difficulty at some time during the course of 
the disease, with progressive worsening. Drooling, dehy-
dration, malnutrition with weight loss and aspiration are 
all associated with dysphagia.
SIALORRHEA AND THICK PHLEGM
Based upon data from the Als patient care Data-
base, 50% of Als patients report sialorrhea and treat-
ment with anticholinergic medication is ineffective or 
poorly tolerated in up to 30% of patients. An alterna-
tive treatment in Als patients with sialorrhea refracto-
ry is Botulinum toxin. in a randomized, double-blind, pla-
cebo-controlled study of the safety and efficacy of Bot-
ulinum Toxin type B (BTXB) for sialorrhea in Als showed 
that the injection of 0.1cc (250U of BTxB) per site at two 
sites in each parotid gland and 0.15cc (750U) per site at 
two sites in each submandibular gland provided an im-
provement of 82% at 2 weeks compared to 38% receiving 
placebo. This significant effect was sustained at 4 weeks. 
At 12 weeks, 50% of patients receiving BTxb continued to 
report improvement compared to 14% receiving place-
bo. There were no significant adverse events, including 
dysphagia, in the BTxb group and no significant increase 
in the rate of decline of vital capacity89.
NUTRITION
Nutrition is an important consideration in the health 
care for any person and the patient with Als is no ex-
ception. care should be taken to have a well balanced 
diet. As Als progress, difficulties in maintaining good nu-
trition may be encountered90. The following suggestions 
may be helpful:
– give enough time to eat. Don’t rush;
– Thin liquids are usually the first to give difficulty. 
Water will “go down the wrong way” more often toma-
to juice will;
– softer foods (eggs, mashed potatoes, pasta) require 
less energy to eat;
– Take smaller bites. chew and swallow carefully;
– consider supplementing meals with calorie shakes, 
or a packaged product, if are not eating enough at meal-
times;
– A daily multivitamin is recommended and adds to 
good general health, although vitamins and other “health 
food” formulas will not make Als better;
– consider a different method, such as feeding tube, 
to get food to the stomach if the patient has: No appe-
tite; Too much weight loss; eating is no longer enjoyable; 
it takes a long time to eat (more than one hour); food is 
“going down the wrong way” daily.
self-feeding aids 
There are various modifications in eating utensils that 
make it easier to feed one self. it is very important to 
check with a rehabilitation or occupational therapist 
about special devices to assist with self feeding. product 
catalogues are available at medical supply stores. some 
examples of these modifications include:
– Built-up handles for flatware and utensils are espe-
cially useful to people with a weak grasp;
– plastic cups and glasses are lightweight and easier 
to hold than glass or china.
Percutaneous endoscopic gastrostomy (PEG)
peg in patients with Als/MND is recommended in pa-
tients with difficulty maintaining good nutrition due to 
pronounced dysphagia. however the timing and the type 
of gastrostomy tube is not consensual. The MND has sug-
gested that peg should be done on the following criteria: 
weight loss of over 10%; severe dysphagia; inadequate 
energy intake; functional vital capacity of less than 50% 
of predicted; history of aspiration and a body mass in-
dex of less than 20. Malnutrition is an independent prog-
nostic factor relating to the survival of patients with Als. 
peg can help to solve this problem, even though patients 
with diminished lung function have an increased mortali-
ty after peg placement. procedure-related mortality can 
reach 1.8%, 24-hour mortality 3.6% and 30-day mortali-
ty 11.5%. The mean survival rate after intervention is ap-
proximately 200 days (185–211 days)91.
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Aggressive proactive nutritional management appears 
essential in patients with Als to prevent silent micro as-
pirations and pneumonia. 
RESPIRATORY PROBLEMS
shortness of breath or other respiratory symptoms usu-
ally occur later in the disease course. symptoms of respira-
tory insufficiency include orthopnea, morning headaches 
and weakness cough. patients develop dyspnea on exer-
tion, with breathlessness during strenuous and then minor 
tasks such as eating or talking. respiratory failure and pul-
monary complications of bulbar paralysis (i.e. aspiration 
pneumonia) are the most common causes of death in Als. 
BRONCHO-PNEUMONIA AND PNEUMONIA
A retrospective pathological study on a large cohort 
of patients demonstrated that broncho-pneumonia and 
pneumonia were the main causes of death (representing 
10% of deaths, that was two times more frequent in bul-
bar than in spinal Als), following by heart failure and by 
pulmonary embolism (representing 6% of death, exclu-
sively found in spinal onset patients and is related to low-
er limbs disability). An effort has to be made for a better 
understanding of the causes of deterioration of Als pa-
tients. A more proactive attitude to treat respiratory in-
fections could have a significant impact on survival92.
DYSPNEA
chronic alveolar hypoventilation is one of the most 
important limiting facors in patients with Als/MND. 
like in other patients with chronic alveolar hypoventila-
tion secondary to other neuromuscular diseases (NMD), 
non invasive ventilation (NiV) has become widely ac-
ceptable for Als patients, as the provision of ventilato-
ry support, providing symptomatic relief and increase life 
expectance93.
While respiratory failure (the major cause of mortal-
ity in patients with Als/MND) is generally a direct con-
sequence of muscle weakness during disease end-stage, 
a proportion of patients develop early and severe re-
spiratory difficulties during sleep, termed nocturnal hy-
poventilation. hypoventilation produces nocturnal hy-
poxia (Nh), which is becoming increasingly recognized 
as a predictor of survival, independent of respiratory 
muscle weakness. patients who had adopted NiV earlier 
were alive longer than those in whom artificial ventilato-
ry support had been initiated later94. even in Als/MND 
patients with symptomatic respiratory failure, it has re-
cently been demonstrated that NiV improves survival95.
patients living longer may be treated at home. When 
necessary the home Mechanical Ventilation (hMV) can be 
applied as non-invasive ventilation (NiV) most often via 
a facemask, or as invasive ventilation via a tracheostomy. 
generally, the use of NiV is much more prevalent than in-
vasive ventilation in Als /MND patients. There are many 
reasons for this, some of which are that NiV is simpler and 
cheaper to administer and the most patients are ventilat-
ed initially during sleep only. eventually, when the need 
for hMV exceeds 16–20/24 hours, some centers would 
consider a change to invasive ventilation. 
diaphragm pacing 
The motor point diaphragm pacing stimulation (Dps) 
system has become a standardized minimally invasive 
laparoscopic procedure to maintain and provide natu-
ral diaphragm ventilation. A prospective pilot and multi-
center pivotal trials of Dps in Als (20 european centers), 
analyzing 73 implanted patients, showed that the Dps 
system can be safely implanted and utilized in Als pa-
tients with a positive effect on diaphragm function. Dps 
minimizes the impact of Non invasive positive pressure 
Ventilation on diaphragm dysfunction and positively im-
pacts patients with identified instability of respiratory 
control96.
PAIN
Als is usually described as causing painless weakness, 
but physical pain can be a surprisingly common symptom, 
affecting 45–64% of Als patients. pain can result from 
loss of mobility and the instability and the inability to 
turn in bed, joint contractures or bedsores. in one study, 
over 50% of patients reported mild pain and 7% report-
ed moderate pain at diagnosis, but by 24 months post di-
agnosis 29% had severe pain requiring level 3 medication 
(including opiates). As pain is a predominant feature for a 
majority of patients its management was identified as an 
area in need of clarification and guidance for the multi-
disciplinary team (MDT). 
for pain management, the recommendations are:
1. Utilize non-narcotic analgesics, anti-inflammatory 
drugs, and antispasticity agents for initial treatment of 
pain in patients with Als.
2. Administer opioids liberally, following the Who 
guidelines, when non-narcotic analgesics fail97.
ELIMINATION
The sphincters that control bowel and bladder func-
tion are voluntary muscle that we learned how to con-
trol in early childhood. it is rare in Als to have weakness 
of these muscles; therefore, Als patients generally do not 
become “incontinent.” But, getting to the bathroom or 
getting on and off the toilet can be a problem. An elevat-
ed toilet seat makes sitting and rising easier. A handrail 
on the side of the toilet may provide needed stability. A 
bedside commode is handy for a person who is very weak. 
Bedpans are not needed for most Als patients.
Arq Neuropsiquiatr 2009;67(3-A)
 773
Amyotrophic lateral sclerosis
oliveira and pereira
Bowel function
The bowel is made of smooth muscle, not voluntary 
muscle and so the bowel itself is not affected by Als. 
however, changes in diet, exercise and fluid intake and 
weakened abdominal muscles can lead to constipation. 
it is possible to manage this by:
– Drinking enough liquids (6–8 glasses a day);
– getting adequate fiber in the diet (bran muffin, 
breakfast cereal, fruits, fibercon);
– Being as active as possible;
– serious constipation can lead to bowel impaction, 
requiring specific treatment;
– Bladder function.
EMOTIONAL LABILITY
emotional lability or pseudobulbar affect due to loss 
of normal inhibition of laughter and crying, complex acts 
that are thought to depend on neural pathways involved 
in emotion, respiration, vocalization and facial move-
ments, may also be associated with UMN degeneration. 
 
PSYCHOLOGICAL AND EMOTIONAL ISSUES
people with Als differ from those with other termi-
nal illnesses in that they commonly retain capacity for 
decision making close to death. The role patients would 
opt to have their families play in decision-making at the 
end of life may therefore be unique98.
Depression is common in Als, but, if properly man-
aged, psychiatric consultation usually is unnecessary. oc-
casionally, an overwhelming catastrophic reaction to the 
disease, stress-induced adjustment problems or marital 
problems stemming from stress may become serious is-
sues. in these instances, a psychiatry or clinical psychol-
ogy referral may be necessary. 
SPIRITUALITY
part of palliative care is tending to the spiritual needs 
of the dying. patient’s spiritual health affects their deci-
sions about medical care. Those with greater spirituality 
are more likely to have advance directives, less likely to 
undergo gastrostomy, less fearful of death and dying, less 
likely to participate in support groups and more likely to 
choose a natural death rather than mechanical ventila-
tion99. religion and spirituality ease adaptation and the 
ability to cope with the process of dying100.
Depending upon the severity and/or the frequency of 
the clinical disturbances, symptomatic medications can 
provide benefits and improve the quality of life (Table 14)101.
PALLIATIVE CARE
currently, all of Als care is palliative. The palliation 
at the very end of life, when death is near, is a time when 
specialist care is needed to avoid physical suffering. An-
ticipating symptoms before they occur is crucial to prop-
er management. The physician and the patient should 
share in decision making, understanding that cultural 
and religious values will have an impact on decisions. 
The physician should explain the risks and benefits of 
treatments at each visit in an unbiased way, and under-
stand that the patient’s choices could change as the dis-
ease progress. As Als progresses, the goal of patient care 
changes from maximizing function to providing effective 
and compassionate palliative care102.
COMMUNICATION 
The technological revolution has expanded commu-
nication options for people with Als who cannot rely on 
natural speech and writing. The assistive technologies are 
categorized as Augmentative and Alternative communi-
cation (AAc) devices. A systematic review of AAc devic-
es reveals 4 critical variables that are manipulated with-
in clinical and research domains: language representation, 
output, motor access, and microprocessor units. language 
representation has received significant attention for rate 
enhancement. While most Als patients spell and rely on 
typing as a form of input, they can never approach speech 
production rates; often the slowness of AAc devices re-
duces their utility. Devices are being designed now that in-
tegrate natural language processing and prediction algo-
rithms for word, utterance and even conversational level 
units as we try to approach natural speaking rates. The out-
put mode has seen advances in speech technology for the 
storage of digitized voice as well as qualitative improve-
ments to synthetic speech. Voice banking is often consid-
ered as an early treatment option, where pAls with intact 
motor speech skills store their spoken words, phrases, sen-
tences and sounds for future use in customized communi-
cation devices. The personalized voice and messages can 
be used along with standard text-to-speech output to re-
tain the pAls’ voice signature. engineering efforts to cus-
tomize synthetic speech to the user’s own voice through 
minimal speech sampling is in progress. speech scientists 
continue to tackle the gold standard for a device: bad 
speech in and good speech out, with attention being paid 
to recognition of dysarthric speech and production of per-
sonalized voices (1). Motor access problems are being ad-
dressed with visual evoked potentials, detection of alpha 
and theta waves, and eye gaze recognizers so that head, 
shoulders, knees and toes are no longer needed. Most de-
vices now offer a range of access methods, starting with 
keyboards, touch screens, a head mouse, and Morse code. 
finally, microprocessor units are available in every shape 
and size to meet the needs of the user, from pDAs to lap-
tops made of magnesium-alloy shells, to software that can 
be downloaded from the internet and accessed through 
any home computer103.
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SEXUALITY AND INTIMACY
Although Als has no direct effect on male or female 
genitalia or fertility, there are many indirect effects. Many 
commonly used medications can adversely effect erec-
tion and orgasm. Weakness and spasticity cause mobility 
problems, which impair sexual expression. physical harri-
ers are worsened by fears of injuring the ill partner and 
guilt about normal desires. few health care providers raise 
the issue – either from a lack of comfort in discussing the 
subject or from a fear that this issue might be perceived 
as trivial in a disease so serious. 
All patients should be asked if they have concerns 
about sexuality. for example, one could phrase the ques-
tion as follows:” Many Als patients have concerns about 
sexuality. if you have questions, feel free to ask.”
Als poses a great challenge to couples. pre-existing 
patterns and problems with communication may be ex-
acerbated. like other life challenges, the diagnosis offers 
Table 14. Symptomatic medications for ALS.
symptom Medication Dosage
Anxiety Buspirone
Diazepam
lorazepam
Mirtazapine
10 mg TiD
5 mg TiD
0.5–1.0 mg BiD
5–30 mg qhs
Depression Bupropion
Mirtazapine
ssri antidepressants
Tricyclic antidepressant
Venlafaxine
100 mg TiD
15–30 mg qhs
20–100 mg qd
20–100 mg qd
37.5–75 mg BiD-TiD
emotional lability ssri 20–100 mg qd
cramps Quinine sulfate
Vitamin e
phenytoin
Diazepam
260–325 mg qd
400 iU TiD
300 mg qhs
2–10 mg TiD
fatigue Amantadine
Modafinil
pemoline
Bupropion sr
fluoxetine
Venlafaxine
pyridostigmine
100 mg qAM, qnoon
100–200 mg qAM
18.75–93.75 mg qd
150–450 mg qd
20–80 mg qd
75–225 mg qd
60 mg TiD
fasciculation gabapentin
phenytoin
300–600 mg TiD
300 mg qhs
sialorrhea Triciclic antidepressants
Atropine sulfate
scopolamine transdermal patch
glycopyrrolate
hyoscyamine sulfate
Diphenhydramine
20–100 mg qhs
0.4 mg q 4–6 hours
1–2 ophthalmic drops sl q 4–6h
Transcop TTT – q 7 days
1–2 mg TiD
0.125–0.25 mg q 4 hours
25–50 mg TiD
spasticity Baclofen
Dantrolene
Tizanidine
Benzodiazepines
10–60 mg TiD
25–100 mg TiD
2–8 mg QiD
260–325 mg qd
Urinary urgency oxybutynin
Amitriptyline
Tolterodine
oxytrol patches
2.5–5 mg BiD
25–75 mg qhs
1–2 mg BiD
3.9 mg qd
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an opportunity for growth and a risk for distance. of the 
many challenges patients face, changes in roles within the 
relationship can be the most painful. 
spouses become caregivers, and it often becomes dif-
ficult to maintain the spouse role.
Acknowledge to couples that their relationship roles 
will change as the illness progress and offer alternatives 
for support such as clergy counselling, mental health re-
ferral, or a sex therapist. 
GENETIC COUNSELING
A DNA-soD1 or DNA-VApB tests speeds up the diag-
nostic process and can be of help in patients with atypi-
cal features as well as providing prognostic information. 
genetic counseling can be better provided to the pa-
tient and relatives. presymptomatic (predictive) genet-
ic testing should only be performed in first-degree adult 
blood-relatives of patients with a known soD1 or VApB 
gene mutation. Testing should only be performed on a 
strictly volunteer basis. special consideration should be 
taken before presymptomatic testing is performed in 
families where the mutation is associated with reduced 
disease penetrance or with a variable prognosis. 
COMPLEMENTARY ALTERNATIVE MEDICINE
complementary and Alternative Medicine (cAM) is 
defined as “a group of diverse medical and health-care 
systems, practices, and products that are not presently 
considered to be part of conventional medicine”. The use 
of cAM has increased in recent years. Many individuals 
with Als/MND self-prescribe alternative treatments, es-
pecially dietary supplements. As health care providers, we 
have the responsibility to provide our patients with sound 
information to make informed decisions about treatment 
modalities and products104.
CAREGIVERS
caregiver burden is a major issue in Als, especially 
when social supports are lacking. Many studies of care-
giver needs suggest that there is a predictable pattern 
of specific needs, and that Qol for caregivers is related 
to characteristics of the patient’s disease, living arrange-
ments and other individual differences. future studies 
should examine the relationship of need satisfaction to 
Qol as well as the potential of caregiver support pro-
grams to meet identified needs and improve Qol105.
RECENT LESSONS LEARNED AND PATH FORWARD 
several therapies have shown promise in preclinical 
models of motor neuron disease. several of these treat-
ment approaches, however, failed in human studies. in 
moving forward with new promising therapies, it is im-
portant to first identify whether the past trials were un-
successful due to wrong therapy and biological target or 
because of flaws in trial design and conduct. Better bio-
markers of disease and markers of biological activity of 
the therapies under development are urgently needed. 
obtaining information regarding dosage, pharmacokinet-
ics, short-term safety and biological activity in well de-
signed phase i and ii studies is critical to the design of 
phase iii trials that will yield meaningful results106.
From clinical trials: minocycline
considerable laboratory evidence suggested that mi-
nocycline possesses anti-apoptotic and anti-inflamma-
tory activity, and may act as a neuroprotective agent. 
four published reports showed that minocycline extend-
ed survival in the soD-1 rodent model. The potential 
neuroprotective effects of minocycline have been ex-
amined in models of other neurological conditions and 
numerous trials are planned to assess whether minocy-
cline may slow the course of human neurodegeneration. 
A randomized placebo-controlled trial of minocycline 
was performed at 31 centers in the United states. After a 
4 month lead-in phase, 412 patients were randomized to 
either minocycline in escalating doses up to 400 mg/day, 
or placebo, for 9 months. patients underwent monthly 
evaluations during their 13 months of participation. The 
outcome measures were Alsfrs-r, fVc, MMT, quality of 
life (Qol), survival, and safety. The results were not ex-
pected. high-dose minocycline has a harmful effect on 
Als as measured by the Als f-r. The Alsfrs-r deteri-
orated at a 25% faster rate (p=0,005) in the minocycline 
group and MMT tended to deteriorate more rapidly in 
the treated group107.
Many apparently effective treatments in open trials 
(trials lacking a concurrent placebo group) fail in larger 
double-blind trials, in which neither doctor nor patient 
knows whether the patient is receiving the study drug.
The finding that minocycline has a harmful effect on pa-
tients with Als has implications for trials of minocycline 
in patients with other neurological disorders, and for how 
potential neuroprotective agents are screened for use in 
patients with Als.
Stem cells explored as als therapy
stem-cell transplantation is an attractive strategy for 
neurological diseases and early successes in animal models 
of neurodegenerative disease generated optimism about re-
storing function or delaying degeneration in human beings. 
Autologous or allogeneic stem cells, undifferenti-
ated or transdifferentiated and manipulated epigeneti-
cally or genetically, could be a candidate source for lo-
cal or systemic cell-therapies in many diseases. The re-
stricted potential of adult stem cells has been challenged 
over the past years by reports on their ability to acquire 
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new unexpected fates beyond their embryonic lineage 
(transdifferentiation)108.
Bone-marrow has been a source of derived stem cells – The col-
lected cells are cultured it in the lab for about two weeks, 
before bone-marrow cells have the ability to divide into 
neural cells with the potential for treating neurological 
disorders to divide into neural cells.
A potential treatment based on injecting stem cells into the spi-
nal cord – With the lack of effective drug treatments for 
Als, and compelling preclinical data, stem-cell research 
has highlighted this disease as a candidate for stem-cell 
treatment. 
stem cell therapy is under development as a possi-
ble treatment approaching Als/MND. italian researchers 
have performed an exploratory trial in a few Als patients 
of using their own stem cells collected from bone marrow 
as therapy. These stem cells do not appear to differ from 
those collected from healthy people. The first experiment 
was presented by letizia Mazzini at 13th international sym-
posium on Motor Neurone Disease, in Melbourne, Austra-
lia. The autologous bone-marrow-derived stem cells in-
jected into the spinal cord (chest level) of seven Als pa-
tients showed a reasonable margin of clinical safety and 
maybe some positive results on disease evolution109,110. A 
more recent and similar pilot study of intra spinal injec-
tions of mesenchymal stem cells (Msc) has been conduct-
ed in 9 Als patients, demonstrating to be a secure pro-
cedure. A possible good effect, with slowly progression, 
was detected four patients, but the appropriate controls 
will need to be included in other experiments to see if the 
treatment does have effect. A new phase 1 study is carried 
out to verify these data in a larger number of patients111.
so far, stem cell treatment trials on Als patients have 
demonstrated some short-term beneficial effects, but in 
the long term the prognosis is not so optimistic.
Human embryonic stem cells – Many scientists say the 
stem cells derived from embryos have a greater poten-
tial for developing into treatments than adult stem cells, 
but this type of research raises some questions. oppo-
nents of embryonic stem cell (esc) research consider re-
search using embryonic stem cells unethical and argue 
that research on adult stem cells is finding cures, too. 
some countries prohibit the destruction of the (esc) 
for research purposes or restrict the federal grants for 
the labs that perform research with this type of cell. 
Besides of the limitations, a team of scientists from the 
University of Wisconsin-Madison has shown it is possi-
ble to rescue the dying neurons characteristic of Als. A 
nascent brain cells known as neural progenitor cells de-
rived from human fetal tissue were engineered to secrete 
a chemical known as glial cell line derived neurotrophic 
factor (gDNf), an agent that has been shown to protect 
neurons but that is very difficult to deliver to specific re-
gions of the brain. The engineered cells were then im-
planted in the spinal cords of rats afflicted with a form 
of Als. When implanted, “the (gDNf secreting) cells sur-
vive beautifully. in 80 percent of the animals, a nice ma-
turing transplants was seen.” The implanted cells, in fact, 
demonstrated an affinity for the areas of the spinal cord 
where motor neurons were dying. According to svendsen, 
the cells migrate to the area of damage where they “just 
sit and release gDNf.” But while the motor neurons ex-
posed to gDNf were protected, the Wisconsin team was 
unable to detect the connections between the neurons 
and the muscles they govern. “even in animals that had 
lots of motor neurons surviving, we didn’t see the (mus-
cle) connection, which explained why we didn’t see func-
tional recovery,” says suzuki. “We think the cells are safe, 
and they do increase the survival of the motor neurons,” 
svendsen argues. “This may be very important for patients 
that lose neurons every day. however, it’s not a trivial in-
tervention - you have to drill a hole in the spinal cord to 
get the cells releasing gDNf in. But there are few options 
for these patients and we will continue to move forward 
with this approach”112,113.
Different forms of cell transplantation therapy are be-
ing tested in models of Als. While the approach offers 
hope to patients with Als, much still needs to be learned 
in the laboratory before it is ready for human trials. Nev-
ertheless, clinics across the world offer various types of 
open label cell transplantation therapy for high fees.
Lessons from Beijing 
Unproven cell-based treatments for ALS/MNd 
Olfactory ensheathing glia injections in Beijing: misleading pa-
tients with ALS – hundreds of patients from across the Unit-
ed states, europe and around the world, including Brazil, 
have flocked to Beijing, china, where Dr. huang hongyun 
implants olfactory ensheathing glia (oec) cells in pa-
tients with degenerated or traumatic diseases. Dr. huang 
hongyun’s explains that oeg cells come from nasal mu-
cosa, which migrates to the olfactory nerve through the 
cribiform plate to the olfactory bulb. Due to the presence 
of olfactory ensheathing cells (oec) the olfactory nerve 
is known to regenerate throughout adult life. he says that 
these cells are thought to help nerves repair themselves 
by releasing growth factors and their amazing healing 
powers should help patients who cannot be helped with 
any other modern medicine.
huang’s website includes profiles of patients he has 
treated for a wide variety of conditions (including Als as 
well as well spinal cord injury) and different symptoms, 
yet huang treats them all with the same cells. Working at 
chaoyang and West hills (Xishan) hospitals, huang’s team 
extracts these cells from aborted fetuses and then opens 
up a hole in the patient’s brain or spinal cord, injecting the 
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cells. in presentations at scientific conferences, he has said 
he has helped many patients and has seen no serious side 
effects. patients have come forward to say that huang 
has helped them, inspiring stories in American and British 
newspapers about a chinese doctor who has maybe, just 
maybe, stumbled upon a modern scientific miracle.
since 2004, Dr huang has been invited to explain his 
work in scientific meetings, but until now, he was not able 
to draw any conclusions from his research because he had 
not gathered enough conclusive data.
evaluations of the patients before-and-after the Bei-
jing procedure, by Dr. Bruce h. Dobkin (medical director 
of the Neurologic rehabilitation and research program 
at the University of california, los Angeles), by Dr. James 
guest (Miami project to cure paralysis and the Univer-
sity of Miami Miller school of Medicine), by Dr. Armin 
curt (Balgrist) and by leonard van den Berg (rudolf Mag-
nus institute of Neuroscience, University Medical cen-
ter Utrecht, Netherlands) showed there were no mean-
ingful improvements in any of the followed patients af-
ter the surgery114.
huang’s treatment has been considered as part of a 
seismic shift in alternative therapies. There have always 
been clinics that cater to desperate patients, offering 
them unproven, often expensive, treatments. But the 
boom in stem cell science and the hype surrounding it 
have brought an explosion of clinics around the world 
that offer therapies based on living cells. huang’s fees can 
reach into the tens of thousands of dollars. 
The results until now are not just disappointing, they 
are disturbing. A woman who received an injection into 
each frontal lobe in Beijing was reported and her Als pro-
gressed at a more rapid rate after the procedure and she 
suffered disabling side-effects. clinics that give experi-
mental and potentially harmful treatments outside the 
construct of well-designed115.
Lessons from lithium
lithium is a simple chemical substance approved for 
use in humans and prescribed as a mood stabilizer. in the 
soD1 g93A mouse model of Als, lithium administration 
results in significant neuroprotection, resulting in delay 
of disease onset and increased lifespan. in these motor 
neurons in vitro, lithium has been shown to (1) reactivate 
the macroautophagy function (through a mechanism of 
inositol monophosphatase inhibition), (2) remove defec-
tive mitochondria and induce mitogenesis, (3) suppress gli-
al cell activation (astrocytosis), which has been implicat-
ed in the Als disease process, (4) decrease α-synuclein, 
ubiquitin, and soD1 aggregation, (5) suppress glutamater-
gic excitotoxicity, and (6) possibly induce neurogenesis (in 
the spinal cord)116.
These experimental results prompted a pilot study by 
fornai et al on the clinical effects of lithium in Als pa-
tients117. They conducted a 15-month randomized, parallel-
group trial of 44 adult sporadic Als patients (20 male, 24 
female) with duration of disease <5 years, most of them 
with the classic onset, but 11 with the bulbar form. six-
teen subjects were randomized to riluzole 100 mg/day 
+ lithium carbonate (300 mg/day to 450 mg/day accord-
ing to lithium concentration’s plasma range of 0.4–0.8 
meq/l) and 28 subjects to riluzole alone. subjects were 
assessed at baseline and every 3 months for 15 months. All 
lithium-treated subjects were alive at the end of the 15-
month follow-up. in marked contrast, about 30% of the 
riluzole-only subjects had died. The data showed that in 
the lithium-treated subjects, the disease progressed very 
slowly: the Alsfrs-r and Norris scale drops from base-
line were not significant (14.3% and 10.6%, respectively), 
whereas in the riluzole group the decreases were all sig-
nificant (39.8% [p<0.05] and 46.1% [p<0.01], respectively). 
Although physical criteria (Mrc and fVc) for disease pro-
gression were evident in the lithium group, they were sig-
nificantly lessened compared with the riluzole controls: 
muscle strength decreased 18.0% in the lithium group ver-
sus 34.8% in the riluzole-only group; fVc remained signifi-
cantly higher in the lithium group (>80% of baseline) rela-
tive to the riluzole group, in which it had fallen to almost 
60% of baseline. Thus, the overall results indicated that 
lithium significantly delays clinical Als progression. 
The magnitude of these effects (lithium delays pro-
gression of Als) has generated great excitement in the Als 
community, increasing the impetus for new research and 
new treatment strategies. To date no other treatment has 
shown such a dramatic effect on this fatal disease. how-
ever, this was a very small study and the design was prob-
lematic: The study did not indicate the criteria for choos-
ing subjects or whether they were consecutive. The pla-
cebo group was (unusually) much larger than the active-
treatment group, and the number of study completers was 
not given. even the causes of death in the control group 
were not specified. Nor was it a completely blinded study, 
which raises the question of whether the groups were 
treated equivalently with respect to possible life-prolong-
ing interventions, ie, bilevel positive air pressure (BipAp) 
or percutaneous endoscopic gastrostomy (peg) tubes. 
Due to diagnostic and prognostic variability in per-
sons showing symptoms of Als, the small numbers in this 
study were not sufficient to know whether lithium was in-
deed an effective treatment. 
PATIENTS LIKEME
patientslikeMe is a privately funded company dedi-
cated to making a difference in the lives of patients diag-
nosed with life-changing diseases. The personal experi-
ences with Als (lou gehrig’s disease) inspired the found-
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ers to create a community of patients, doctors, and or-
ganizations that inspires, informs, and empowers individ-
uals. They are committed to providing patients with ac-
cess to the tools, information, and experiences that they 
need to take control of their disease. The more patients 
that share their information, the more power is possible 
to detect any important aspect in Als history.
A collaborative project which was first initiated by 
Karen felzer, phD. and humberto Macedo, along with all 
the patients involved in the “lithium spreadsheet” who 
have demonstrated such leadership to this community. 
All patients were encouraged to have an effective consul-
tation with their doctor to take lithium, to join patient-
slikeMe and share your data with the world. Today, pa-
tientslikeMe has data on the progression and history of 
more than 1600 Als patients - twice the number in the 
largest Als trial in history. The results were presented in 
the last symposium on Als / MND, at Birmingham, eng-
land. About 250 patients worldwide who had elected to 
start taking lithium, in collaboration with their doctors, 
have been tracking their progression and blood levels on 
patientslikeMe. No difference has been found on survival, 
historical forced vital capacity, the Als functional rating 
scale, and a full symptom battery for most of the patients 
who have started, as well as for all the other non-lithium 
users of the system. contrary to the italian study, sever-
al users presented side effects118. Because lithium is a po-
tentially toxic drug, it must be taken under a doctor’s su-
pervision with frequent monitoring of blood levels. com-
mon side effects include muscle tremors, twitching, kid-
ney damage, and seizures
in experimental research, lithium carbonate treatment 
did not improve the disease progression in two different 
strains of soD1 mutant mice119.
Besides of these results and considerations, a larger, 
randomized, controlled and multicentric study of lithi-
um to determine whether the initial findings are truly a 
new treatment for Als or the result of chance and small 
sample size120.
FUTURE
Als appears now a more complex disease than it did 
two decades – or even one decade – back, but new in-
sights have been plentiful. clinical trials should be seen 
more as experiments on pathogenic mechanisms. More 
rigorous criteria for moving from cellular and animal mod-
els to man should be agreed to avoid time-wasting studies. 
ideally, we need to identify biomarkers (eMg studies, csf 
analysis, and imaging techniques) that will indicate wheth-
er the supposed target has been modified. Understanding 
of the mechanisms of soD1 Als may at last be crystallis-
ing into more focused hypotheses, and treatments are be-
ing developed to modify this form of disease. 
DRUGS
The involvement of apoptotic mechanisms in the neu-
ronal loss of Als is one argument that raises the possibil-
ity of a final common pathway underlying different neu-
rodegenerative disorders, including Als, Als-variants, Al-
zheimer’s disease, fronto-temporal dementia and parkin-
son’s disease, and hence a potential for the development 
of common treatment modalities121.
ARIMOCLOMOL
Arimoclomol is an investigational drug for Als that 
amplifies heat shock protein gene expression during cell 
stress. A preliminary study, including eighty-four partic-
ipants receiving arimoclomol at one of three oral doses 
(25, 50, or 100 mg three times daily) or placebo. to assess 
the safety, tolerability, and pharmacokinetics of arimocl-
omol in Als has been finished. The primary outcome mea-
sure was safety and tolerability. A subset of 44 partici-
pants provided serum and cerebrospinal fluid (csf) sam-
ples for pharmacokinetic analysis. participants who com-
pleted 12 weeks of treatment could enroll in a 6-month 
open-label study. Arimoclomol at doses up to 300 mg/
day was well tolerated and safe. Arimoclomol resulted in 
dose-linear pharmacologic exposures and the half-life did 
not change with continued treatment. Arimoclomol csf 
levels increased with dose. Arimoclomol was shown to be 
safe, and it crosses the blood-brain barrier. serum pharma-
cokinetic profiles support dosing of three times per day. 
An efficacy study in Als is planned122.
COMBINATION DRUG SELECTION TRIAL
A combination of drugs acting on different mecha-
nisms of neurodegeneration may be necessary to reach 
meaningful outcomes in Als trials. Moreover, gene ex-
pression profiling and genome-wide association studies, 
together with inhibitory rNA techniques, are helpful for 
developing new pharmacotherapeutic strategies including 
gene therapy. it is also likely that the recently advanced 
generation of induced pluripotent stem cells will lead to 
the development of cell therapy for Als123.
Multiple pathways have been implicated in the patho-
genesis of Als. A medication or combination of medica-
tions that targets more than one pathogenic pathway may 
slow disease progression in an additive or synergistic fash-
ion. such combination therapy has been successful in on-
cology, though multiple drug interactions and increased 
incidence of drug side effects should be considered.
Vascular endothelial growth factor (VEGF) 
receptor-1 and its Ligand VEGF-B
The 60 kDa Vegf-B isoform, Vegf-B(186), is a neu-
roprotective factor, protecting cultured primary motor 
neurons against degeneration. When delivered intracere-
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broventricularly, Vegf-B(186) prolonged the survival of 
mutant soD1 rats. compared with a similar dose of Vegf, 
Vegf-B(186) was safer and did not cause vessel growth or 
blood-brain barrier leakiness. The neuroprotective activity 
of Vegf-B, in combination with its negligible angiogenic/
permeability activity, offers attractive opportunities for 
the treatment of neurodegenerative diseases124.
 
IMMUNOTHERAPY
immunotherapy is emerging as a therapeutic ap-
proach in neurodegenerative diseases characterized by 
deposition of aggregated and/or misfolded proteins, in-
cluding amyotrophic lateral sclerosis (Als). in familial 
Als (fAls1) cases harboring mutations within the gene 
encoding super oxide dismutase-1 (soD1), soD1 aggre-
gates are found in motor neurons and in astrocytes. Al-
though the precise molecular mechanisms of motor neu-
ron degeneration caused by mutant soD1 remains to be 
elucidated, it is suggested that toxicity is related to the 
propensity of the mutant protein to misfold and/or to 
dissociate from a dimer into a monomer, and ultimate-
ly to form aggregates. We have recently developed an 
antibody that recognizes monomeric/misfolded soD1 
called soD1-exposed-Dimer-interface (seDi) antibody. 
This antibody was generated to a peptide sequence cor-
responding to the dimeric interface of soD1 (seDi pep-
tide) and therefore only detects soD1 when this inter-
face is exposed. Using the seDi antibody, we have detect-
ed the presence of monomeric/misfolded soD1 in motor 
neurons of three lines of mutant soD1 transgenic mice 
(g93A, g37r and g85r) and fAls cases carrying soD1-
mutations. Vaccination of soD1g 3 7r mice transgenic 
mice with seDi peptide or soD1 aggregates delayed the 
onset and slowed the progression of disease. immuniza-
tion increased life expectancy, improved motor deficits, 
and reduced motor neuron degeneration. These results 
suggest that immunotherapy against pathological mono-
meric/misfolded soD1 or soD1 aggregates effectively 
improves motor and pathological disease outcomes. An 
immunotherapeutic approach that specifically targets 
misfolded soD1 therefore provides promise for devel-
opment of a novel therapy for the treatment of fAls1125.
IGF-1 - VIRAL DELIVERY 
Adeno-associated virus engineered to contain the 
gene for igf-1 (AAV-igf1) allows targeted delivery of igf-1 
to motor neurons. After iM injection, the gene vector is 
transported to the neuronal cell body by retrograde ax-
onal transport along motor neurons126. AAV-igf-1 prolongs 
median survival by 30% (37 days) when administered be-
fore disease onset. human safety, dose schedule, and 
pharmacokinetics have not yet been established for this 
novel gene therapy, though AAV-factor iX vector has prov-
en safe in patients with hemophilia127. A small phase iia tri-
al of AAV-igf-1 is planned for the near future. expansion 
of the viral vector production capacity will be required 
before proceeding to large scale trials.
EMBRYONIC STEM CELLS AND PROSPECTS 
FOR THEIR USE IN REGENERATIVE MEDICINE 
APPROACHES TO MOTOR NEURONE DISEASE
human embryonic stem cells are pluripotent cells 
with the potential to differentiate into any cell type in 
the presence of appropriate stimulatory factors and en-
vironmental cues. Their broad developmental potential 
has led to valuable insights into the principles of devel-
opmental and cell biology and to the proposed use of hu-
man embryonic stem cells or their differentiated prog-
eny in regenerative medicine. stem cell-derived motor 
neurones could conceivably be used in Als’ patients to 
replace the degenerated cells, to provide authentic sub-
strates for drug development and screening and for fur-
thering our understanding of disease mechanisms. how-
ever, to reliably and accurately culture motor neurones, 
the complex pathways by which differentiation occurs in 
vivo must be understood and reiterated in vitro by em-
bryonic stem cells128.
The success of cell-replacement therapy in Als will 
depend a lot on preclinical evidence, because of the 
complexity and precision of the pattern of connectivi-
ty that needs to be restored in degenerating motor neu-
rons. stem-cell therapy will need to be used with other 
drugs or treatments, such as antioxidants and/or infusion 
of trophic molecules.
FAMILIAL ALS
There is no specific therapy for patients with a soD1 
gene mutation but a number of projects are underway 
to develop techniques (rNAi, antisense therapy) to in-
activate the mutant soD1 gene to prevent the synthesis 
of the cytotoxic mutant soD1 protein. however, finding 
a patient to be a carrier of a soD1 gene mutation can be 
of advantage to the patient. 
Als Brazilian Association (ABrelA – Associação Brasileira 
de esclerose lateral), founded on 1999, with the aim of at-
tempt to sole the needs of the Als and other motor neu-
ron disease patients, offers orientation for the patients, 
their families, caregivers and other health professionals, 
about the care needs for a best quality of life. More infor-
mation can be reached at: e-mail: abrela@abrela.org.br - 
site: www.abrela.org.br - www.tudosobreela.com.br
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